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ABBREVIATIONS
ACS acute coronary syndrome
ACT activated clotting time
ADP adenosine 5´-diphoshate
APC activated protein C
AT antithrombin
BSA bovine serum albumin
CRP collagen-related peptide
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
F factor
F1+2 prothrombin fragment 1+2
GFP gel-fi ltered platelets
GP glycoprotein
MI myocardial infarction
MP microparticle
PAI-1 plasminogen activator inhibitor-1
PCI percutaneous coronary intervention
PBS phosphate-buffered saline
PAR protease-activated receptor
PCA procoagulant activity
PE phosphatidylethanolamine
PF 4 platelet factor 4
PPACK D-phenylalanyl-L-prolyl-L-arginine chloromethylketone
PS phosphatidylserine
PPP platelet-poor plasma
PRP platelet-rich plasma
SCCS surface-connected canalicular system
SD standard deviation
SEM scanning electron microscopy
TAT thrombin-antithrombin III complex
TF tissue factor
TFPI tissue factor-pathway inhibitor
TRAP thrombin receptor-activating peptide
TXA2 thromboxane A2
VWF von Willebrand factor
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ABSTRACT
Objective: The role of platelets in hemostasis and arterial thrombosis involves their ad-
hesion to sites of vessel injury or ruptured atherosclerotic plaque, aggregation to form a 
hemostatic plug or a thrombus, and acceleration of coagulation leading to thrombin gen-
eration and subsequent formation of an insoluble fi brin clot. Activated platelets promote 
coagulation by interacting with several coagulation factors and the subsequent formation 
of thrombin and fi brin further activates platelets, thus leading to explosive amplifi cation of 
thrombin generation. Despite the important functional role of platelets in directing throm-
bus formation at the site of vascular injury, relatively little is known about their procoagu-
lant activity (PCA) induced by permanent adhesion to a thrombogenic surface. The aim 
of this study was to investigate the effect of the adhesion of platelets to a thrombogenic 
surface on their subsequent procoagulant activation and the role of specifi c adhesive recep-
tors in mediating this activation.
Methods and Results: Our study design provided activation of platelets by their fi rm ad-
hesion to collagen or a plasma clot, with subsequent procoagulant alteration of the platelet 
phospholipid membrane. Permanently adhered platelets showed markedly enhanced PCA 
when compared with maximally activated platelets in suspension. The adhesion-dependent 
procoagulant capacity of platelets varied inter-individually but surface-independently over 
3-fold. Activation of platelets by their fi rm adhesion was accompanied by formation of 
procoagulant microparticles. A monoclonal antibody against glycoprotein (GP) Ib, SZ2, at-
tenuated platelet-dependent thrombin generation by 40% alone and by 65% in combination 
with abciximab. Blockade of the GP IIb/IIIa receptor by an antibody Fab fragment, abcixi-
mab, reduced platelet PCA and formation of prothrombin fragments F1+2 by 35%. Despite 
equal inhibition of platelet deposition on collagen, abciximab decreased platelet-dependent 
PCA signifi cantly more than the synthetic GPIIb/IIIa inhibitors tirofi ban or eptifi batide both 
under static and blood fl ow conditions. None of the antagonists inhibited platelet factor 
(PF) 4 release from adhering platelets. The effects of the three GPIIb/IIIa antagonists on 
platelet aggregation induced by several procoagulant GPVI-related agonists; collagen-re-
lated peptide (CRP), convulxin, or collagen fi brils, was assessed with a turbidometric ag-
gregometer in PPACK-anticoagulated platelet-rich plasma. At concentrations that equally 
inhibited ADP- and collagen-induced maximal aggregation, abciximab inhibited GPVI-
mediated responses to CRP or convulxin signifi cantly more than the low-molecular-weight 
antagonists. Inhibition of fi brin polymerization by Gly-Pro-Arg-Pro (GPRP) potentiated 
tirofi ban and eptifi batide to achieve the same effect as abciximab, although GPRP did not 
affect platelet aggregation in the absence of GPIIb/IIIa antagonists.
Conclusions: Platelet adhesion to a thrombogenic surface causes strong procoagulant ac-
tivation and formation of procoagulant microparticles. Marked inter-individual but sur-
face-independent variation in platelet procoagulant capacity suggests a uniform platelet 
10
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procoagulant mechanism. Additive reduction of platelet-dependent coagulation activity 
by blockade of GPIIb/IIIa and GPIb supports the involvement of both receptors in the 
regulation of platelet PCA. At similar anti-aggregatory effi cacy abciximab decreased the 
PCA of adherent platelets more than the low-molecular-weight antagonists, dissociating 
the inhibitory effects on platelet aggregation and PCA. All GPIIb/IIIa antagonists failed to 
affect PF 4 release from adhering platelets, suggesting distinct mechanisms for secretion 
and procoagulant activation. Furthermore, GPIIb/IIIa antagonists exhibit distinct inhibition 
profi les on platelet aggregation triggered by procoagulant GPVI-related agonists, depend-
ing on fi brin polymerization and divalent cations.
11
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INTRODUCTION
Platelet adhesion to exposed subendothelial components of injured vessels, with the result-
ing formation of platelet-rich clots, is associated with various forms of arterial thrombosis, 
i.e. myocardial infarction, stroke and peripheral arterial disease. Subendothelial collagen 
and von Willebrand factor (VWF) are the initial adhesive ligands leading to primary plate-
let adhesion with subsequent activation and aggregation. Simultaneously, the coagulation 
system is activated by subendothelial or blood-borne tissue factor (TF). Activated plate-
lets accelerate coagulation by releasing coagulation factor (F) Va and by exposing a pro-
coagulant phospholipid surface for the assembly of several enzymes, cofactors and substrate 
molecules of the coagulation cascade, thus leading to explosive amplifi cation of thrombin 
generation. Arterial thrombus propagates as a result of coagulation activation leading to the 
formation of thrombin and fi brin, both of which further enhance the procoagulant activa-
tion of platelets. This interplay establishes a powerful resonance loop between platelets 
and coagulation in which the adhered and activated platelets have a fundamental role in 
localizing coagulation activity at the site of vascular injury, thus preventing disseminated 
intravascular coagulation, and in protecting the coagulation enzymes from inactivation by 
several inhibitors in plasma. The platelet surface also localizes the negative-feedback reac-
tions of coagulation, such as inactivation of factors Va and VIIIa by activated protein C. 
In addition to platelets, platelet-derived microvesicles provide the mandatory procoagulant 
phospholipid surface, thus lowering the threshold at which activated clotting factors will 
induce explosive thrombin formation.
Despite the important functional role of platelets in directing the coagulation system 
and its regulation at the site of injury, the contribution of specifi c platelet receptors and their 
adhesive ligands responsible for enhanced procoagulant activity (PCA) has only recently 
gained interest.
To date, relatively little is known about the procoagulant capacity of adherent platelets 
on a thrombogenic surface. Most studies have essentially used purifi ed coagulation factors 
instead of plasma, or have been performed with plasma and platelets in suspension or in 
whole blood in the absence of adhesive ligands.
Due to the multiple interactions of platelets and coagulation proteins in arterial throm-
bosis both antiplatelet agents and anticoagulants have proved effective in the prevention 
and treatment of arterial thrombotic events. Antiplatelet agents primarily decrease platelet 
activation at the site of vascular injury, thus leading to reduced aggregation and thrombus 
formation. This inhibition of platelet accumulation causes a quantitative decrease in plate-
let-dependent coagulation activity by diminishing the access of procoagulant phospholipid 
membranes and platelet secretion products at the thrombus site. However, relatively little 
is known about the direct effects of antiplatelet agents on the procoagulant capacity of 
platelets. 
The present study was designed to investigate the procoagulant activity of platelets 
induced by their permanent adhesion to a thrombogenic surface. This approach is validated 
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by the fact that adhesion to an injured vessel wall (or pre-formed thrombus) is the primary 
and most physiological route to platelet activation. Moreover, we assessed the roles of 
specifi c adhesive receptors and their antagonists on the adhesion-triggered procoagulant 
activation of platelets. The studies concerning the effects of glycoprotein (GP) IIb/IIIa
antagonists on platelet procoagulant capacity contribute to the knowledge of clinical effi cacy 
and safety of these antiplatelet drugs, especially in combination with anticoagulants.
13
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REVIEW OF THE LITERATURE
1. PLATELETS
Human platelets are small anucleate cells approximately 2 μm in diameter which exhibit 
considerable variation in size and shape depending on their activation state. Platelets are 
generated by fragmentation of megakaryocytes in the bone marrow and typically circu-
late for 10 days before they are removed by macrophages (George 2000). Normal platelet 
counts in blood range from 150 to 400 × 109/L. Multifunctional platelets are involved in 
many physiological and pathophysiological processes including hemostasis and thrombo-
sis, clot retraction, vessel constriction and repair, host defence, infl ammation – including 
promotion of atherosclerosis – and tumor growth or metastasis (Harrison 2005).
1.1. Morphology
Platelet surface
Platelet plasma membrane is a trilaminar unit composed of a bilayer of phospholipids in 
which cholesterol, glycolipids, and glycoproteins are embedded (White & Clawson 1980). 
In resting platelets, the outer leafl et of the plasma membrane consists mainly of neutral 
phospholipids, whereas the negatively charged aminophospholipids, phosphatidylserine 
(PS) and phosphatidylethanolamine (PE), are almost exclusively present in the inner leafl et 
(Bevers et al. 1982). While these anionic phospholipids are able to accelerate several steps 
in plasma coagulation, their localization on the inner side of resting platelets is a crucial 
mechanism to prevent inappropritate coagulation (Zwaal & Schroit 1997). This asymmet-
ric lipid organisation is maintained by various membrane enzymes acting cooperatively 
and syncronously (reviewed in Heemskerk et al. 2002). In resting platelets, the phospholi-
pid composition is maintained by an aminophospholipid translocase (Bevers et al. 1999) 
promoting inward transport of aminophospholipids. The loss of this phospholipid trans-
membrane asymmetry, and the consequent surface exposure of PS and PE, is likely to be 
mediated by a Ca2+-dependent phospholipid scramblase activity and concomitant inhibition 
of aminophospholipid translocase activity (Comfurius et al. 1996, Bevers et al. 1999).
Glycocalix, a fuzzy layer of membrane glycoproteins (GP), glycolipids, mucopolysac-
carides, and adsorbed plasma proteins, coats the outside surface of the plasma membrane, 
providing a transfer point for plasma proteins as they are taken up into secretory granules by 
endocytosis, and producing a net negative surface charge mainly due to sialic acid residues 
attached to proteins and lipids (Coller 1984). This electrostatic repulsion is likely to prevent 
resting platelets from attaching to each other and to the negatively charged endothelium.
14
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Platelet membranous systems
The surface-connected canalicular system (SCCS) consists of an elaborate series of con-
duits contiguous with the surface plasma membrane coursing throughout the platelet in-
terior (Kaushansky & Roth 2004). It acts as an internal membrane reservoir to facilitate 
platelet spreading and fi lopodia formation upon adhesion. Additionally, it holds a storage 
pool of membrane glycoproteins, such as GPIIb/IIIa, that increases on the platelet surface 
after activation.
The dense tubular system is a closed-channel network of residual endoplasmic reticu-
lum involved in the regulation of intracellular calcium transport (Cutler et al. 1978). The 
dense tubular system is also the main site of prostaglandin synthesis in platelets (Gerrard 
et al. 1978).
Cytoskeleton
The discoid shapes of resting platelets and their ability to contract and spread upon activa-
tion depend on a cytoplasmic network of monomers, fi laments and tubules constituting the 
platelet cytoskeleton (Fox 2001). The membrane cytoskeleton associates with the cytoplas-
mic domains of several transmembrane glycoproteins and appears to regulate the surface 
mobility of GP receptors (Nurden et al. 1994). Upon platelet activation and the rise of 
intracellular calcium, soluble monomeric actin (G-actin) polymerizes into fi laments (F-actin) 
at the platelet periphery, and bundles of new fi laments fi ll the developing fi lopodia. Binding 
of myosin to actin provides the tension required for granule centralization and retraction 
of fi lopodia. Additional proteins, such as talin and actin-binding protein, further cross-link 
the actin fi laments and link the membrane cytoskeleton with surface glycoproteins. Cyto-
skeletal rearrangements, with the development of a contractile ring, is also associated with 
secretion, although the actual site of granule membrane fusion remains unclear (Kaushansky 
& Roth 2004).
Secretory granules
Platelets possess secretory granules containing several molecules affecting platelet func-
tion, coagulation and fi brinolysis, vascular tone and wound healing. Some of the constitu-
ents are synthesized and segregated by megakaryocytes, others are taken up from plas-
ma and incorporated into the granules (Kaushansky & Roth 2004). The main secretory
constituents of platelet cytoplasm and granules; α-granules, dense granules, and lysosomes, 
are listed in Table 1. Upon activation, the granules fuse with the platelet surface mem-
brane and extrude their contents. This granule secretion is a graded process depending on the
nature, number, and concentration of the original stimulus/stimuli, either strong (i.e. 
thrombin and collagen) or weak (i.e. ADP and epinephrine) (Packham et al. 1977). 
15
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Regulation of intracellular calcium
Unstimulated platelets maintain low cytoplasmic Ca2+ concentrations (100 to 500 nmol/L) 
by limiting Ca2+ transport from plasma and promoting active effl ux. Two pools of calcium 
exist in platelets: a cytosolic pool regulated by a sodium-calcium antiporter in the plasma 
membrane and a more slowly exchanging pool in the dense tubular system regulated by 
calcium, magnesium-ATPase (Kaushansky & Roth 2004).
Table 1.  Major contents of platelet secretory granules and cytoplasm.
α-granules
• Platelet-specifi c proteins
e.g. platelet factor 4, β-thromboglobulin
• Adhesive glycoproteins and α-granule membrane-specifi c proteins
e.g. fi brinogen, von Willebrand factor, thrombospondin, fi bronectin,
vitronectin,
P-selectin, multimerin
• Coagulation factors, coagulation inhibitors, fi brinolysis inhibitors
e.g. factor V, protein S, plasminogen activator inhibitor-1
• Mitogenic and angiogenic factors
e.g. platelet-derived growth factor, vascular endothelial growth factor,
transforming growth factor-β
• Other proteins
e.g. albumin, immunoglobulins
Dense granules
• Adenosine diphosphate (ADP)
• Adenosine triphosphate (ATP)
• Calcium
• Serotonin
Lysosomes
• Acid hydrolases
e.g. elastase, collagenase, cathepsins, heparinase
Cytoplasm
• Factor XIII, tissue factor pathway inhibitor
References: Ware & Coller 1995; Kaushansky & Roth 2004
16
Review of the Literature
1.2. Adhesive platelet receptors
GPIb/IX/V
GPIb/IX/V (usually named the GPIb complex) is a set of four single-chain polypeptides 
(GPIbα, GPIbβ, GPIX and GPV) that mediates the shear-dependent interaction between 
platelets and VWF (Coller et al. 1983a) (Fig. 1). The binding of VWF to the GPIb complex 
causes platelet activation through activation of protein kinase C, phosphatidylinositol 3-ki-
nase and tyrosine kinases, leading to an increase in intracellular calcium and to inside-out 
signaling through GPIIb/IIIa followed by aggregation (Berndt et al. 2001). Patients with 
Bernard-Soulier syndrome lack or have defi cient levels of GPIb and GPIX and exhibit a 
bleeding diasthesis (Lopez et al. 1998). The active site within the A1 domain of the VWF 
chain binds GPIbα, and this structure is distinct from the Arg-Gly-Asp (RGD)-containing 
sequence in VWF that interacts with the GPIIb/IIIa receptor (Vicente et al. 1990). The ini-
tial step of platelet tethering depends on the GPIb complex and subendothelial VWF, whose 
affi nity requires shear forces generated by arterial blood fl ow (Kroll et al. 1996). This inter-
action between the GPIb complex on resting circulating platelets and immobilized VWF at 
the site of arterial injury leads to the initial capture of platelets to subendothelium, making 
possible their activation and subsequent fi rm adhesion (Savage et al. 1996). However, the 
interaction between the GPIb complex and VWF is rapidly reversible, seen as rolling of 
platelets on the VWF-containing surfaces, and is insuffi cient for stable thrombus forma-
tion (Fredrickson et al. 1998). Under static conditions these components display very low 
Actin-binding protein
GPIb / IX / V
CD42
GPIX GPIbβ
GPIbα GPIbα
GPIX
GPIbβ
von Willebrand factor and
thrombin binding site
GPV
ss ss
Fig. 1. Structure of platelet glycoprotein (GP) complex Ib/IX/V. Adapted from www.nibsc.ac.uk, 
Division of Haematology.
17
Review of the Literature
affi nity for each other, and an exogenous stimulus, such as ristocetin, is needed to induce 
high affi nity binding (De Luca et al. 2000). This shear-dependence of the initial adhesive 
receptor-ligand interaction of platelets explains the predisposition of platelet-rich thrombus 
in the arterial circulation, whereas in the venous circulation with lower shear forces clot 
formation is largely independent of the GPIb complex. 
GPIbα also possesses a high-affi nity binding site for thrombin and the GPIb complex 
serves as a thrombin receptor after cleavage of the GPV chain (Ramakrishnan et al. 2001). 
Recent studies also suggest a relationship between thrombin binding to the GPIb complex 
and activation of the protease-activated thrombin receptor PAR-1 (De Candia et al. 2001), 
as well as accelerated procoagulant activation of platelets (Dörmann et al. 2000). Previ-
ously, Loscalzo et al. (1986) observed that VWF serves as a link between polymerizing 
fi brin and platelet GPIb. Beguin et al. (1999, 2004) have reported that fi brin-associated 
platelet procoagulant activity is mediated via the GPIb complex and VWF. In addition, 
Factor XI binds to the GPIbα chain on the surface membrane of activated platelets (Baglia 
et al. 2002), where it is activated by thrombin (Baglia & Walsh 1998) and then activates 
FIX in an alternative pathway to TF-FVIIa (Gailani et al. 2001). The GPIb complex can 
also be considered as an indirect collagen receptor while VWF is attached to subendothelial 
collagen and this binding together with shear conditions leads to conformational changes 
of VWF and high-affi nity binding to the GPIb complex. In addition, the GPIb complex was 
found to interact with the Fc receptor (FcR) γ chain, and activation of the GPIb complex 
induced similar, though weaker, tyrosine phorphorylation as collagen (Wu et al. 2001). 
Recently, Cruz et al. (2005) demonstrated that interaction of platelet GPIb with VWF medi-
ates the activation of GPIa/IIa, thus increasing its affi nity for collagen.
Collagen receptors
Several types of collagens have been localized in the vessel wall. Fibrillar types I and III 
are the major constitutes of the vessel wall, although the network-forming type IV collagen 
is the principal form in basement membranes (Kehrel 1995). The concentrations of these 
collagens have been shown to increase in the intima of atherosclerotic lesions (Barnes 
1985). Collagen types I, III and IV are the most platelet-reactive, capable of inducing both 
adhesion and aggregation (Sixma et al. 1997). However, fi brillar collagen usually consists 
of a mixture of several collagen types along with other matrix components. Recently, Ber-
nardo et al. (2004) proposed that fi brillar collagen may contain a varying quantity of VWF, 
enhancing platelet adhesion to collagen and subsequent platelet activation. Horm collagen, 
the most commonly used commercial preparation in platelet studies, consists mainly of 
equine collagen type I along with a small amount of type III collagen and low levels of 
other extracellular matrix proteins. 
While searching for platelet-reactive sites of collagen, Morton et al. (1995) found that
a collagen mimetic peptide containing 10 repeats of the Gly-Pro-Hyp sequence induced 
platelet aggregation independent of GPIa/IIa. This collagen-related peptide (CRP) strongly
activates platelets, especially when cross-linked, stimulates tyrosine phosphorylation 
in platelets in a similar manner as collagen (Asselin et al. 1997), and is inhibited by an
18
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antibody against GPVI (Knight et al. 1999). Convulxin, a venom protein from the tropical 
rattlesnake Crotalus durissus terrifi cus, has been shown to be an agonist of GPVI (Polgar 
et al. 1997), but also to bind to GPIbα (Kanaji et al. 2003). 
The mechanisms of signal transduction underlying the activation of platelets by col-
lagen have been actively investigated for over three decades, but the functional signifi cance 
of the receptors involved remains incompletely understood. At high shear rates platelet 
adhesion to collagen requires VWF (Sixma et al. 1997). Cho et al. (2003) demonstrated 
that the secondary mediators thromboxane (TXA2) and adenosine diphosphate (ADP) are 
required for collagen-induced platelet activation in response to low collagen concentra-
tions (2.5 μg/mL) and that GPIIb/IIIa-mediated outside-in signaling is responsible, at least 
in part, for this TXA2 production and ADP secretion. However, large concentrations of 
collagen (50 μg/mL) induce GPIIb/IIIa activation and weak aggregation response even in 
the absence of the secondary mediators. In contrast, GPVI-specifi c agonists induce activa-
tion of GPIIb/IIIa without any signifi cant involvement of ADP or TXA2 (Nieswandt et al. 
2001a, Quinton et al. 2002).
GPIa/IIa
GPIa/IIa (integrin α2β1) was the fi rst collagen receptor to be identifi ed on platelets (Santoro 
1986). It is an α-β heterodimer mediating platelet adhesion to collagen in a Mg2+-depend-
ent manner (Fig. 2). According to the classic “two-site, two-step” model, GPIa/IIa medi-
ates fi rm adhesion to collagen, thereby allowing platelet interaction with the low-affi nity 
receptor GPVI, mainly responsible for collagen-induced platelet activation (Farndale et 
al. 2004). However, the role of GPIaIIa in mediating platelet-collagen interactions is still 
GPIa / IIa
VLA - 2
α2 β1
CD49b / CD29
GPIIa GPIa
COOHCOOH
s
s
s
s
s
s
Collagen binding site 
I domain
Fig. 2. Structure of platelet glycoprotein (GP) Ia/IIa. Adapted from www.nibsc.ac.uk, Division of 
Haematology. 
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FcR γ-chain
S
S
S
S
GPVI
salt bridge
Fig. 3. Structure of platelet glycoprotein (GP) VI. Adapted from Clemetson et al. 1999.
controversial. The previous model has been challenged by observations that propose initial 
interaction between GPVI and collagen leading to subsequent conformational activation of 
GPIa/IIa (as well as GPIIb/IIIa), reinforced by the released secondary mediators (ADP and 
TXA2) causing stable adhesion to collagen and thereby further platelet activation via GPVI 
(Nieswandt & Watson 2003). Jung and Moroi (2000) fi rst showed that the affi nity of GPIa/
IIa for collagen is regulated by intracellular signals, suggesting that under resting condi-
tions the affi nity of GPIa/IIa for collagen is low, whereas several platelet agonists, including 
ADP, TXA2, and GPVI-specifi c stimuli, remarkably increase this binding affi nity (Moroi et 
al. 2000). Recently, Cruz et al. (2005) demonstrated that interaction of platelet GPIb with 
VWF mediates the activation of GPIa/IIa, thus increasing its affi nity for collagen. On the 
contrary, data from a GPVI knock-out mouse model (Kato et al. 2003) and from studies with 
human platelets using a novel single chain antibody fragment against GPVI (Siljander et al. 
2004) showed that fl ow conditions in the absence of GPVI lead to loss of aggregation but 
not primary adhesion, suggesting that GPIa/IIa (together with the GPIb/VWF axis) indeed 
plays a dominant role in platelet adhesion to collagen. In addition, recent data have provided 
evidence about signaling through GPIa/IIa (Keely & Parise 1996, Inoue et al. 2003).
GPVI
Although GPVI was identifi ed on the platelet surface over 20 years ago (Clemetson et al. 
1982), its role in collagen-mediated platelet activation has been resolved much later. Quite 
recently cloned and characterized, GPVI is a member of the immunoglobulin (Ig) receptor 
superfamily containing two IgC2-like extracellular domains formed by disulphide bonds, 
a transmembrane region, and a short cytoplasmic tail (Clemetson et al. 1999), and exclu-
sively expressed on platelets and megakaryocytes (Fig. 3). The strength of intracellular 
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signals arising from ligand binding to GPVI seem to depend on the ability of the agonist to 
cross-link and induce clustering of GPVI (Farndale et al. 2004). The expression of GPVI 
on platelet membranes is closely associated with the Fc receptor (FcR) γ-chain, which also 
serves as the main signaling unit for GPVI (Tsuji et al. 1997, Nieswandt et al. 2000). Only 
a few GPVI-defi cient patients have been reported to date, suffering from a mild bleeding 
tendency and lacking platelet aggregation in response to collagen (Moroi & Jung 2004). A 
number of polymorphic variations at the GPVI locus have been identifi ed, but their clinical 
signifi cance remains unclear (Joutsi-Korhonen et al. 2003, Yee & Bray 2004). Furihata et 
al. (2001) observed a 5-fold variability in human platelet GPVI content, correlating with 
the GPVI-mediated prothrombinase activity. 
It is now recognized that stable platelet plug formation on collagen under high shear 
rates requires signaling through GPVI, reinforced by the release of soluble secondary me-
diators such as ADP and TXA2 or by generation of thrombin (Kato et al. 2003, Moroi & 
Jung 2004, Siljander et al. 2004). Nieswandt et al. (2000) observed that FcRγ-defi cient and 
GPVI-depleted mouse platelets showed no adhesion to collagen under static or fl ow condi-
tions in the presence of normal levels of GPIa/IIa, GPIb complex, and GPIIb/IIIa. How-
ever, this defective adhesion was restored in the presence of Mn2+, which directly activates 
GPIa/IIa (Nieswandt et al. 2000), or agonists that can activate GPIa/IIa through inside-out 
signaling (Inoue et al. 2003). This suggests a role for GPVI in generating the intracellular 
signal to promote integrin (GIa/IIa and GPIIIb/IIIa) activation rather than in serving as an 
adhesion receptor. In contrast, Kato et al. (2003) observed in a mouse knock-out model that 
absence of GPVI did not affect primary adhesion of platelets to collagen whereas platelet 
aggregation upon the initial layer was inhibited. Studies with human platelets have pro-
vided controversial results. Goto et al. (2002) recently reported almost complete abolition 
of platelet deposition to collagen with two GPVI-defi cient patients. Blocking of GPVI with 
a single-chain antibody fragment 10B12 abolished aggregation, Ca2+ signaling, and pro-
coagulant response of human platelets without affecting primary adhesion to collagen in 
a whole blood perfusion model at high shear (Siljander et al. 2004). Blocking of GPIb or 
GPIa/IIa, or both receptors, markedly reduced primary adhesion and aggregate formation, 
whereas combined inhibition of GPVI and GPIb or GPIa/IIa completely abolished primary 
adhesion to collagen.
Suzuki et al. (2003) demonstrated that platelets have internal pools of GPVI on the 
membranes of SCCS and α-granules, and that GPVI is transported to the platelet surface 
membrane and to microparticles during activation. A recently identifi ed mechanism for 
regulating GPVI function on platelets is metalloproteinase-mediated ectodomain shedding 
in response to binding of collagen, CRP, or convulxin to GPVI and followed by release of a 
soluble 55-kDa GPVI fragment (Gardiner et al. 2004). This process involving the calmodu-
lin-binding site may represent a control mechanism for GPVI-dependent platelet adhesion 
and activation.
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Fig. 4. Structure of platelet glycoprotein (GP) IIb/IIIa. Adapted from www.nibsc.ac.uk, Division of 
Haematology.
GPIIb/IIIa
GPIIb/IIIa (integrin αIIbβ3) is the major surface receptor, present in 40 000 to 80 000 copies, 
on the plasma membrane of a resting platelet (Fig. 4). It is a transmembrane heterodimer con-
sisting of a two-chain disulphide-linked α subunit with four divalent cation-binding domains 
and a disulphide bond-rich β subunit (McEver et al. 1982). The short cytoplasmic domains 
of the two subunits are critical for transmembrane signaling and anchor the receptor to the 
cytoskeletal elements. Another 20 000 to 40 000 receptor copies are localized inside the 
platelets, mainly in the membranes of α-granules and SCCS, capable of joining the platelet 
surface membrane upon platelet secretory activation (Wencel-Drake et al. 1986, Phillips et 
al. 1988). Cycling of GPIIb/IIIa between the platelet surface and α-granule membrane has 
been described (Wencel-Drake et al. 1993). Previous data suggest that this movement could 
be involved in fi brinogen transport into α-granules (Harrison 1992). Platelet activation causes 
mobilization of these intracellular fi brinogen-GP IIb/IIIa complexes to the platelet surface in 
a secretion-dependent manner (Legrand et al. 1989, Nurden et al. 1996). GPIIb and GPIIIa 
require Ca2+ to maintain their heterodimeric structure (Jennings et al. 1982), and the receptor 
complex undergoes a Ca2+-dependent conformational change after platelet activation, strong-
ly facilitating binding of fi brinogen and VWF (Sims et al. 1991). The outcome is cross-link-
ing of GPIIb/IIIa receptors on adjacent platelets and subsequent platelet aggregation. 
GPIIb/IIIa binds to a variety of RDG-containing ligands, including fi brinogen, fi bro-
nectin, VWF, vitronectin, and thrombospondin (Plow et al. 1985). However, the major 
ligand site of fi brinogen on the C-terminus of the γ domain lacks the RGD sequence (Farrell 
et al. 1992). The binding affi nity depends on the activation state of the GPIIb/IIIa complex 
and varies both between ligands as well as between soluble and immobilized forms of 
a ligand. In addition, the plasma coagulation protein prothrombin was shown to act as a
ligand for a resting GPIIb/IIIa complex (Byzova & Plow 1997). Prothrombin bound to GPIIb/
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IIIa on a resting platelet can be cleaved by coagulation factor Xa resulting in the release 
of thrombin. Thrombin in turn can activate platelets through specifi c receptors (PAR-1 
and -4) (Coughlin 1999) causing activation of GPIIb/IIIa receptors. The activated receptor 
then prefers binding fi brinogen over prothrombin. This early formation of soluble thrombin 
through resting GPIIb/IIIa receptors is suggested to cause initial procoagulant activation of 
the platelets, leading to further thrombin generation by the prothrombinase complex on the 
activated platelet membranes (Byzova & Plow 1997).
Platelet agonists such as ADP, collagen, or thrombin activate GPIIb/IIIa through a 
complex inside-out signaling process leading to confomational changes of the receptor to 
a high affi nity state (affi nity modulation), and clustering of the heterodimers to oligomers 
through lateral diffusion (avidity modulation) (Shattil 1999). In addition, more GPIIb/IIIa 
is translocated onto the platelet surface from the membranes of α-granules and SCCS upon 
platelet shape change and secretion. After ligand binding, the subsequent signaling process, 
termed outside-in signaling, modulates platelet spreading and stabilizes platelet-platelet 
interactions (Casserly & Topol 2002). 
In addition to its roles in platelet adhesion, aggregation, and procoagulant activity, 
GPIIb/IIIa is also crucial in mediating clot retraction (Coller et al. 1983b), although the 
exact mechanism and clinical signifi cance of this process remains controversial. Like the 
GPIb complex, GPIIb/IIIa can be considered as an indirect collagen receptor because sub-
endothelial VWF acts as bridging molecule between platelets and collagen. This interaction 
between activated GPIIb/IIIa and  subendothelial collagen via VWF supports stable platelet 
adhesion and thrombus formation.
Glanzmann thrombasthenia is a rare hereditary bleeding disorder characterized by 
decreased or functionally abnormal platelet GPIIb/IIIa causing a substantial reduction in 
platelet aggregation (Nurden & Caen 1974, Phillips & Agin 1977). Early studies on the 
procoagulant capacity of platelets from patients with Glanzmann thrombasthenia yielded 
confl icting data, but Reverter et al. (1996) observed a decreased rate and amount of plate-
let-dependent thrombin generation in these patients. Gemmel et al. (1993) reported that 
platelets of a Glanzmann thrombasthenia patient showed markedly reduced microparticle 
formation in response to thrombin stimulation, whereas Nomura et al. (1993) observed 
normal MP generation in response to several platelet agonists. 
Additional receptors related to adhesion
Other integrin receptors for specifi c intracellular matrix components include receptors for 
fi bronectin (α5β1) (Piotrowicz et al. 1988), laminin (α6β1) (Sonnenberg et al. 1988), and 
vitronectin (αvβ3) (Lam et al. 1989). PECAM-1 binds to heparin-like molecules and may 
contribute to platelet-heparin interactions and the interactions of platelets with other cells 
(Albelda et al. 1991). P-selectin is translocated from the membranes of platelet α-granules 
to the surface membrane upon activation and mediates adhesion of neutrophils and mono-
cytes to activated platelets, thus connecting platelet activation and infl ammation (Larsen et 
al. 1989). In addition to P-selectin and the recently discovered CD40/CD40 ligand-pathway 
on platelets (reviewed in Danese & Fiocchi 2005), receptors for the Fc fragment of IgG 
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(FcγR) are considered to be a contact link in the immune system. The only FcγR expressed 
on platelets is FcγRIIa, an integral membrane protein with two extracellular Ig-like do-
mains (Rosenfeld et al. 1985). 
1.3. Platelet receptors for soluble agonists
Thrombin receptors
In addition to the GPIb complex (after cleavage of GPV) described above, two G-protein-
coupled protease-activated receptors (PAR-1 and PAR-4) serve as thrombin receptors on 
human platelets (Coughlin  1999). On these receptors, the ligand is already present as an 
amino acid sequence SFLLRN (residues 42–47) on the extracellular chain and becomes 
unmasked after thrombin cleavage of a peptide bond between Arg 41 and Ser 42. Thereafter 
this sequence irreversibly binds to the body of the receptor to affect transmembrane signal-
ing. A synthetic peptide mimicking the PAR-1 ligand sequence, thrombin receptor-activat-
ing peptide (TRAP), is capable of activating the receptor independent of the cleavage of 
the peptide bond. The PAR-1 receptor is connected to a signifi cant number of intracellular 
signaling pathways causing rapid platelet shape change, secretion, aggregation, and cal-
cium mobilisation. Agonists of the PAR-1 receptor induce relatively weak procoagulant 
responses, whereas agonists to PAR-4 do not stimulate PS exposure (Andersen et al. 1999). 
After activation, PAR-1 is rapidly uncoupled from signaling and internalized into platelet 
lysosomes for degradation (Hoxie et al. 1993). Several studies show physiologic differ-
ences between PAR-1 and PAR-4 receptors on human platelets. Blocking the PAR-4 recep-
tor alone has no effect on thrombin-mediated platelet activation, whereas with antibodies 
against the thrombin interaction site of PAR-1 the PAR-4 receptor is functional only at high 
thrombin concentrations (Kahn et al. 1999).
ADP receptors
Although considered as a weak platelet agonist, ADP has a critical role in amplifying the ef-
fects of other platelet agonists. It is synthesized by megakaryocytes, stored at high concen-
trations in platelet dense granules and released upon platelet stimulation. ADP can directly 
induce platelet shape change, aggregation, and secretion, although the last event depends 
on the formation of TXA2 (Meyers et al. 1979). ADP interacts with P2 receptors which are 
divided into two groups; the G protein-coupled P2Y family and the ligand-gated ion chan-
nel P2X family (reviewed in Cachet 2001). Two P2Y receptors, P2Y1 and P2Y12, contrib-
ute to platelet activation. The primary role of the P2Y12 receptor is to act as a co-stimulus 
in the presence of low concentrations of other agonists, whereas the P2Y1 receptor has a 
specifi c role early in platelet activation. P2X1 is the third platelet receptor for ADP, but 
its exact role remains unclear. Inhibition of ADP-associated platelet activation with clopi-
dogrel has proven effective in the prevention of arterial thrombosis (CAPRIE 1996). This 
antithrombotic effect of clopidogrel’s active metabolite is thought to be mediated through 
covalent modifi cations of the P2Y12 receptor (Savi et al. 2000).
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Receptors for other soluble agonists
Platelet responses to epinephrine are mediated through α2 adrenergic receptors. Unlike other 
platelet agonists, epinephrine does not induce shape change, although it induces aggre- 
gation and secretion (Siess et al. 1984). Epinephrine enhances platelet activation induced 
by other agonists in a synergistic fashion, whereas it may reverse the effects of aspirin on 
thrombus formation (Mustonen & Lassila 1996, Mustonen et al. 2001). Activation of plate-
lets by various agonists liberates arachidonic acid which then is converted into thrombox-
ane A2 by cyclo-oxygenase-1, itself irreversibly inhibited by aspirin through acetylation of 
a serine residue near its C-terminus (Roth & Calverley 1994). After its release into plasma 
TXA2 is capable of activating other platelets although its half-life is only 30 seconds. The 
TXA2 receptor is a member of the transmembrane G protein-coupled receptor family local-
ized on platelet plasma membranes. In addition, platelets have G protein-coupled receptors 
for serotonin (5HT2A), vasopressin, and platelet-activating factor, although the clinical 
signifi cance of these receptors in vivo remains unclear (Kaushansky & Roth 2004). 
2. COAGULATION
A cascade or waterfall model of coagulation was originally proposed by two groups in 
1964 (Davie & Ratnoff 1964, MacFarlane 1964), and subsequently refi ned to a scheme 
consisting of intrinsic and extrinsic coagulation pathways (Fig. 5) refl ected by the clinical 
laboratory tests activated partial thromboplastin time (aPTT) and prothrombin time (PT), 
respectively. However, several groups have questioned the signifi cance of separate intrinsic 
Fig. 5. Former model of the coagulation cascade with intrinsic and extrinsic pathways. F: factor; 
HMWK: high-molecular-weight kininogen; PK: prekallikrein; PL: phospholipid; TF: tissue factor.
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and extrinsic pathways and emphasized the role of cellular components in the regulation of 
coagulation (Gailani & Broze 1991, Hoffman & Monroe 2001, Butenas & Mann 2002). 
2.1. Initiation of coagulation
Tissue factor (TF), also known as thromboplastin or CD142, is a 47 kDa transmembrane 
cell surface glycoprotein and the principal initiator of the coagulation cascade in vivo 
(Nemerson 1966, Bach 1988). It is expressed at extravascular sites, particularly in richly
vascularized organs, forming a protective procoagulant envelope around the vasculature.
Pathological expression of TF occurs in macrophage-derived foam cells and smooth
muscle cells of atherosclerotic lesions, in certain cancer cells, and in monocytes of patients 
with Gram-negative endotoxemia/sepsis (reviewed in Eilertsen & Østerud 2004). Recently, 
several studies have demonstrated the existence of circulating TF in blood (reviewed in 
Giesen et al. 1999). TF antigen has recently been reported to exist intravascularly in multi-
ple forms: as a soluble protein, as a membrane protein in microparticles, or in monocytes, 
granulocytes, and platelets. One explanation is that TF-bearing procoagulant membrane 
particles (microparticles) shed from one cell type – possibly monocytes – could bind to the 
surface of other cells via adhesive receptors (Rauch et al. 2000, Conde et al. 2003, Eilertsen 
& Østerud 2004). Moreover, activated platelets upregulate TF expression in monocytes 
(Celi et al. 1994) or decrypt the TF of circulating monocytes, and this blood-borne TF is 
thought to be essential in the propagation phase of coagulation (Breimo & Østerud 2003). 
In contrast to microparticle-associated TF in blood, soluble TF seems to be unable to induce 
FVIIa-mediated thrombin generation (Sturk-Maquelin et al. 2003). 
According to the revised models of coagulation (Fig. 6) (Hoffman & Monroe 2001, 
Butenas & Mann 2002), the initiation phase of blood coagulation occurs when TF is ex-
Fig. 6. Current model of coagulation. F: factor;  TF: tissue factor.
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posed due to endothelial damage or systemic or local proinfl ammatory activation of TF-
expressing cells in the vasculature. An active TF-FVIIa is formed due to trace amounts of 
activated factor VII (FVIIa) already present in circulating blood (Morrisey et al. 1993). 
FVIIa is a very weak serine protease on its own but binding to TF enhances its catalytic 
activity more than 106-fold. However, the activity of the FVIIa-TF complex is dependent 
on the presence of a negatively charged phospholipid surface (e.g. phosphatidylserine). 
The FVIIa-TF complex (known as extrinsic factor Xase) activates vitamin K-dependent 
zymogens FIX and FX. Associated with PS on the surface of activated platelets (or plate-
let-derived microparticles), FXa forms a complex with partially activated FV exposed on 
activated platelets, thus generating minute amounts of thrombin (Monkovic & Tracy 1990, 
Monroe et al. 1996). Traces of thrombin subsequently activate plasma factors V and VIII 
in positive feedback reactions and enhance platelet activation in cooperation with exposed 
subendothelial collagen (Butenas et al. 1997).
2.2. Propagation of coagulation
In the propagation phase of blood coagulation FVIIIa associates with the serine protease-
activated FIXa on the anionic phospholipid surface of activated platelets to form the cal-
cium-dependent intrinsic tenase complex (Rosing et al. 1985). This complex activates FX 
at a signifi cantly higher rate than does the FVIIa-TF complex. Subsequently, FXa interacts 
with FVa and prothrombin on a phospholipid surface to form the Ca2+-dependent prothrom-
binase complex, promoting proteolytic cleavage of prothrombin and resulting in a burst of 
thrombin generation. It has been estimated that the presence of phospholipids stimulates 
the prothrombinase complex to convert prothrombin to thrombin 1000- to 100 000-fold 
faster than a physiological concentration of FXa alone (Nesheim et al. 1979, Rosing et al. 
1980). Thrombin propagates the coagulation cascade through further amplifi cation of its 
own generation by activating FXI (which subsequently generates more FIXa), FV, FVIII, 
and platelets, thus leading to sustained interplay between coagulation activity and platelets 
(Pieters et al. 1989, Gailani & Broze 1991, Butenas et al. 1997). The subsequent massive 
thrombin generation ultimately results in an insoluble cross-linked fi brin clot by cleavage 
of fi brinogen (Bailey et al. 1951) and FXIII (Naski et al. 1991). 
2.3. Intrinsic pathway of coagulation
The role of the intrinsic or accessory pathway in normal hemostasis is poorly understood, 
and defi ciencies of FXII, prekallikrein and high-molecular-weight kininogen are not associ-
ated with bleeding problems (Brummel-Ziedins et al. 2004). However, FXI has a prominent 
role in coagulation while it can be activated by thrombin (without activation through the 
intrinsic pathway) and thereafter accelerate coagulation via the extrinsic pathway (Gailani 
& Broze 1991, Oliver et al. 1999).
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2.4. Termination of coagulation
Coagulation activity is regulated by several physiological inhibitors which inactivate either 
serine proteases or their cofactors (Fig. 7). Tissue factor-pathway inhibitor (TFPI) consti-
tutes the major inhibitor of the initiation phase of coagulation (Golino et al. 2002). It is 
present at relatively low concentrations in blood and inactivates FXa and the TF-FVIIa-FXa 
complex (Rapaport 1991). The most abundant physiological anticoagulant, antithrombin 
(AT) III, effectively neutralizes several serine proteases, especially thrombin and FXa, un-
less they are bound to a protective phospholipid surface, and its effect is strongly promoted 
by heparins (Olson et al. 1993). In addition to its strong procoagulant effects, thrombin 
also exhibits anticoagulant properties. After binding to thrombomodulin, thrombin loses 
its anticoagulant capacity and inhibits coagulation by activating the vitamin K-dependent 
protein C on a negatively charged phospholipid surface. Activated protein C (APC) forms 
a complex with protein S to inhibit activated coagulation factors Va and VIIIa, thus leading 
to inhibition of thrombin generation (Kisiel et al. 1977, Esmon et al. 1982). In contrast to 
TFPI, the protein C pathway and AT III have only minor effects on the initiation phase of 
blood coagulation, whereas they constitute the major inhibitors in the propagation phase 
(van’t Veer & Mann 1997a, van’t Veer et al. 1997b). In addition to activating protein C, 
the thrombin-trombomodulin complex protects clot formation by inhibiting fi brinolysis 
through the action of thrombin activatable fi brinolysis inhibitor (TAFI) (reviewed in Bajzar 
2000).  
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Fig. 7. Regulation of coagulation. In addition to FXa and thrombin, antithrombin also inhibits several 
other serine proteases. APC; activated protein C; AT: antithrombin (III); F: factor; TF: tissue factor; 
TFPI: tissue factor-pathway inhibitor. 
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3. PLATELET FUNCTION IN HEMOSTASIS AND THROMBOSIS
3.1. Adhesion, aggregation and secretion
Platelet response to exposed subendothelial matrix is fundamental to initiation of the hemo-
static cascade or thrombosis at the higher shear rates found in arteries. Platelet function in 
hemostasis and thrombosis is a complex process consisting of platelet tethering, adhesion, 
activation, spreading, aggregation, degranulation, procoagulant activation, and microparticle 
generation.
The rapid interaction between the GPIb complex on resting platelets and VWF im-
mobilized on subendothelial collagen is crucial for the capture of platelets from circula-
tion. This interaction is rapidly reversible, seen as rolling of platelets on the surface, and 
thus insuffi cient for stable adhesion. During this initial tethering other direct and indirect 
collagen receptors come into contact with their adhesive ligand sites on subendothelial col-
lagen. According to current knowledge, primary adhesion to collagen is mediated through 
the interplay of the GPIb complex, GPIaIIa, and GPVI. Signaling through GPVI is crucial 
for conversion of the glycoproteins Ia/IIa and IIb/IIIa to the high-affi nity states needed for 
the formation of a stable platelet plug. Following adhesion, rapid signal transduction leads 
to platelet activation causing platelet shape change and spreading on the adhesive surface 
with extrusion of fi lopodia, resulting in formation of a fully spread, fl attened platelet with 
central eminence, resembling a fried egg (Ware & Coller 1995). The extent of degranula-
tion of platelet secretory α- and dense granules is dependent on the strength of the agonist, 
and leads to enhancement of platelet activation and aggregation through release of secondary
platelet activators, fi brinogen, and VWF. Upon activation, platelet surface membrane
GPIIb/IIIa receptors are activated through inside-out signaling to bind soluble fi brinogen
and VWF with high affi nity. Additional GPIIb/IIIa receptors from the SCCS and
α-granules, possibly in a ligand-bound state, are transported to the platelet surface upon 
activation. Adjacent platelets are thus connected to each other to form aggregates. 
3.2. Physiologic inhibition of platelet activation
Platelet activation is inhibited by several mechanisms including the intact endothelial bar-
rier, brief half-life of certain platelet activators (such as TXA2), inhibition of generated 
thrombin by AT, and tendency of blood fl ow to wash away unbound platelet activators. 
Endothelial cells generate nitric oxide (NO) in response to shear stress and other platelet 
activators, and this molecule inhibits platelet activation through cyclic guanyl monophos-
phate (Calverley & Maness 2004). Prostaglandins PGE1, PGE2 and PGI2, inhibit platelet ac-
tivation through G protein-coupled receptors that regulate cyclic adenylate monophosphate 
generation (Calverley & Maness 2004). Moreover, desensitization of activated receptors by 
biochemical modifi cation or their internalization from the platelet surface regulate ongoing 
platelet activation.
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3.3. Platelet procoagulant activity (PCA)
Membrane phopholipids
In an advanced stage of activation platelets stimulate blood coagulation by providing a 
surface at which the coagulation factors are activated to generate thrombin (Bevers et al. 
1982, Rosing et al. 1985, Bevers et al. 1991, Zwaal et al. 1992, Zwaal & Schroit 1997). 
In resting platelets the negatively charged phospholipids PS and PE are situated on the 
inner leafl et of the plasma membrane and this asymmetric distribution is maintained by 
an aminophopholipid translocase (reviewed in Heemskerk et al. 2002). The loss of trans-
membrane asymmetry is mediated by a Ca2+-dependent phopholipid scramblase activity 
and concomitant inhibition of the aminophospholipid transferase (Comfurius et al. 1990, 
Williamson et al. 1995). The signaling pathways that regulate platelet procoagulant activity 
are largely unknown, but both PS/PE exposure and bleb formation are shown to require a 
prolonged rise in intracellular Ca2+ in response to mobilization of intracellular Ca2+ stores 
and infl ux of extracellular Ca2+ (reviewed in Heemskerk et al. 2002). Recently, Bahou et al. 
(2004) described a novel Ca2+-independent but α-granule secretion-dependent intracellular 
signaling pathway involving platelet IQGAP1 that specifi cally regulates the development 
of platelet PCA under high shear conditions in a mouse model. However, the mechanisms 
leading to IQGAP1 activation remain unknown.
Generation of microparticles
During the process of PS and PE exposure, activated platelets change their shape and form 
membrane blebs that are easily shed from the remnant platelet as microvesicles with sim-
ilar procoagulant phospholipid surfaces (Sims et al. 1989, Zwaal et al. 1992, Chang et 
al. 1993). The molecular basis of microvesiculation remains poorly characterized, but it
appears to be Ca2+-dependent and involves calpain and caspase-3 activation, and cytoskeletal
proteolysis (Sims et al. 1989). In the rare hereditary Scott syndrome, impairment of
phospholipid scramblase leads to the absence of both procoagulant surface and microparticle
(MP) generation upon platelet activation, causing bleeding problems (Sims et al. 1989, 
Zwaal et al. 2004). In contrast, patients with Wiscott-Aldrich syndrome have platelets with 
enhanced exposure of procoagulant phospholipids and increased MP release (Shcherbina 
et al. 1999). 
Platelet procoagulant agonists
Initially, it was recognized that Ca2+-ionophores such as A23187 or ionomycin are espe-
cially potent stimulators of platelet PCA and microvesiculation (Bevers et al. 1982). Other
agents that can induce exposure of procoagulant phopholipids on the platelet surface
include Ca2+-mobilizing compounds such as inhibitors of the sarco/endoplasmic reticulum 
Ca2+-ATPases (Dachary-Prigent et al. 1995) and the complement proteins C5-9 (Sims et al. 
1988). Exposure of PCA can also be caused by high shear stress (Miyazaki et al. 1996) or 
experimental cell damage subsequent to freeze-thawing or ultrasonication.
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With isolated platelets in suspension, collagen is incapable of inducing strong pro- 
coagulant activation to support thrombin generation upon activated platelets in the absence 
of thrombin (Bevers et al. 1982, Zwaal et al. 1992). In contrast, platelet adhesion to fi brillar 
collagen, even in the absense of thrombin, can trigger the procoagulant response (Thiagara-
jan & Tait 1991, Heemskerk et al. 1997). The procoagulant activation induced by collagen is 
mediated by GPVI (Nieswandt et al. 2001a, Siljander et al. 2001) and adhesion via GPIa/IIa
serves to potentiate the signaling effects of GPVI (Heemskerk et al. 1999). Accordingly, 
platelet adhesion to the GPVI-specifi c agonist CRP induces procoagulant activation of 
platelets (Heemskerk et al. 1999). 
Controversial data exist on the mechanisms of thrombin-induced platelet PCA. Al-
though a potent agonist for platelet aggregation and secretion, thrombin was proposed to 
cause only little PS exposure when added to isolated, washed platelets (Bevers et al. 1983). 
This weak procoagulant response in the absence of plasma proteins was similar to that in-
duced by agonists of the PAR-1 receptor, whereas agonists of PAR-4 failed to stimulate PS 
exposure (Andersen et al. 1999). However, in the study of Dicker et al. (2001) α-thrombin 
was a strong inducer of procoagulant activity of gel-fi ltered platelets (GFP) in suspension 
whereas the procoagulant capacity induced by the PAR-1 receptor agonist SFLLRN (at 
concentrations causing maximal aggregation and Ca2+ mobilization) was only one fi fth of 
that induced by 10 nM thrombin. In their study, several antibodies against PAR-1 had no ef-
fect on thrombin-induced platelet PCA. Dörmann et al. (2000) postulated that GPIb-bound 
thrombin is mainly responsible for procoagulant activation of GFP after stimulation with 
thrombin in suspension and that this activation requires both PAR-1 and GPIIb/IIIa as well 
as platelet-platelet interaction. Additionally, other groups (Miyata et al. 1996, Jamieson 
1997) have postulated that thrombin-induced platelet PCA is mediated through binding to 
GPIb, although these experimental conditions were devoid of fi brin(ogen). In sharp con-
trast, Liu et al. (1997) suggested that platelet activation by thrombin is exclusively medi-
ated via G-coupled receptors rather than by GPIb. In addition, thrombin may stimulate the 
prothrombinase reaction of isolated platelets by activating factor V, secreted from platelets 
during activation (Briede et al. 2001). 
Procoagulant activity of platelets in plasma
In the presence of plasma proteins, adhesive platelet receptors seem to play a crucial role 
in the procoagulant activation of platelets. Reverter et al. (1996) fi rst described inhibi-
tion of platelet-mediated thrombin generation by the 7E3 antibody against GPIIb/IIIa and 
αvβ3, whereas an antibody against GPIb, 6D1, had no effect on thrombin generation in 
the absence of fi brin. Additionally, platelets from patients with Glanzmann thrombasthenia 
lacking GPIIb/IIIa receptors supported signifi cantly less thrombin generation than normal 
platelets (Gemmel et al. 1993, Reverter et al. 1996, Weiss & Lages 1997).
In platelet-rich plasma (PRP) under static conditions thrombin generation strongly
stimulates platelet procoagulant response (Beguin et al. 1989), acting in concert with forming
fi brin and VWF (Beguin & Kumar 1997, Sanders et al. 1998). In the study of Beguin
et al. (1997), platelet-dependent thrombin generation in PRP was suppressed by antibodies 
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against VWF, while coagulation activity in platelet-poor plasma (PPP) persisted. Kumar 
et al. (1994 and 1995) demonstrated the important role of clot-bound thrombin on further 
platelet activation and observed an additional activating effect of fi brin on the procoagu-
lant action of platelets. Using fi brin clots prepared by snake venom protease and devoid 
of thrombin, Beguin et al. (1999) observed a marked increase of thrombin generation in 
PRP in response to fi brin, while coagulation in PPP remained unaltered. This additional
procoagulant effect was not affected by inhibition of GPIIb/IIIa, whereas antibodies blocking
VWF binding to GPIb prevented the procoagulant effect of fi brin but failed to inhibit 
platelet-dependent thrombin generation in the absence of added fi brin. In accordance,
thrombin generation in PRP of a patient with Bernard-Soulier syndrome was not increased 
after addition of thrombin-free fi brin (Beguin et al. 2004). Prevention of fi brin polymeriza-
tion with antibody A11 or with DRGDW inhibited thrombin generation in PRP despite the 
presence of thrombin (Beguin et al. 2004). Loscalzo et al. (1986) previously reported that 
VWF serves as a link between polymerizing fi brin and platelet GPIb receptor. It has been 
suggested that under static conditions polymerizing fi brin could induce a conformational 
change in VWF similar to that brought about by shear, immobilization, or ristocetin (Soslau 
et al. 2001, Beguin et al. 2004). Briede et al. (2003) demonstrated that shear-dependent 
platelet binding to VWF via the GPIb complex signifi cantly potentiated the procoagulant 
effect of thrombin on platelets deposited on fi brin surface. 
VWF-GPIIb/IIIa interaction also seems to play a role in platelet procoagulant activa-
tion, but only after platelet activation by thrombin (Goto et al. 1995). Decreasing VWF 
activity with a neutralizing antibody inhibited procoagulant activity of PRP both in the 
presence and absence of added fi brin, without affecting thrombin generation in plasma. 
Two separate VWF-dependent mechanisms of platelet procoagulant activation can be sug-
gested: one associated with GPIb and fi brin, and the other with GPIIb/IIIa (Beguin et al. 
1999, Beguin et al. 2004). 
In summary, at a site of arterial injury, platelet-mediated thrombin generation is initiated
on the fi rst platelets adhering to collagen. Subsequently, TF-induced thrombin generation
further accelerates the procoagulant activation of platelets. After formation of a hemostatic 
plug or thrombus, adhesive collagen is sealed and further procoagulant activation of plate-
lets is supported by the fi brin clot, thus promoting a sustained interaction between platelets 
and coagulation. In addition, blocking of purinergic ADP receptors P2Y1 and P2Y12 has 
been shown to reduce platelet procoagulant activity and microparticle release (Herault et al. 
1999, Storey et al. 2000), and platelets from patients with a storage pool defi ciency lacking 
ADP release have reduced platelet-dependent procoagulant capacity (Weiss & Lages 1997). 
Thus, ADP released from platelets upon activation is able to potentiate the procoagulant 
effects of other platelet agonists.
Platelet receptors for coagulation factors
There is accumulating evidence that in addition to negatively charged phopholipids, protein
components of the platelet membrane also have specifi c roles in platelet-dependent
coagulation. Several coagulation factors interact with membrane glycoproteins on resting 
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or activated platelets, thus contributing to platelet PCA, especially in the initiation phase 
of coagulation. Factor XI binds to the GPIbα chain on the surface membrane of activated 
platelets (Baglia et al. 2002), where it is activated by thrombin (Baglia & Walsh 1998) 
and affects thrombin generation induced by TF (Keularts et al. 2001). Gailani et al. (2001) 
observed that FIX can bind to one chain of the dimeric FXIa on the platelet surface and 
become activated by this alternative pathway. There is also evidence for a specifi c, non-
lipid activation-induced binding site for FVIII on platelets (Ahmad et al. 2000). Byzova 
and Plow (1997) demonstrated that prothrombin binds to GPIIb/IIIa on resting platelets. 
Prothrombin bound to GPIIb/IIIa on a resting platelet was cleaved by FXa resulting in the
release of thrombin, which in turn can activate platelets through specifi c receptors leading
to activation of the GPIIb/IIIa receptors. Thus, this pathway of thrombin generation
also contributes to platelet-dependent coagulation, especially during the initiation phase. 
It is possible, that the inhibititory effects or GPIb and GPIIb/IIIa antagonists on platelet 
procoagulant activity may in part rely on blocking the binding of FXI or prothrombin, 
respectively.There are also some data on the existence of a FXa receptor, effector protease 
receptor-1 (EPR-1), on the platelet surface and on its role in regulating prothrombinase 
activity (Bouchard et al. 1997).
Platelet-derived coagulation factors
In addition to providing the procoagulant phospholipid surface and binding sites for
several coagulation factors, platelets contribute to coagulation activity by releasing several
compounds, such as FV, FXIII, fi brinogen, VWF, and protein S. Approximately 20% of FV 
contained in whole blood is found in the α-granules of platelets (Tracy et al. 1982) and can 
be secreted upon platelet activation (Chesney et al. 1981). Several observations indicate 
that platelet-derived membrane-bound FV has a pivotal role in promoting hemostasis at 
sites of vascular injury (Allen et al. 2004). Platelet FV Quebec (Tracy et al. 1984) and New 
York (Weiss et al. 2001) are  bleeding disorders characterized by fully functional plasma 
FV but defective platelet FV, suggesting that platelet-derived FV may be more important 
for normal hemostasis than plasma FV. Accordingly, a patient with an acquired inhibitor 
against both plasma and platelet FV presented with bleeding problems (Grigg et al. 1989), 
whereas another patient with inhibitor against only plasma FV did not suffer from abnor-
mal bleeding tendency (Nesheim et al. 1986). Camire et al. (1998) observed that platelet- 
derived but not plasma-derived FV is protected from proteolytic inactivation by APC on the 
platelet surface. A proportion of platelets (enriched in young platelets) stimulated with both 
collagen and thrombin (COAT platelets) express high levels of α-granule-derived factor V 
on their surface membrane and this expression parallels the surface exposure of procoagu-
lant phospholipids (Alberio et al. 2000). Factor Xa preferentially binds to these platelets, 
leading to enhanced prothrombinase activity when compared with other platelets (Alberio 
et al. 2000). COAT platelets also retain serotonin-conjugated procoagulant proteins on their 
surface (Dale et al. 2002) by interaction with specifi c receptors or by serotonin-binding 
sites on fi brinogen or thrombospondin (Szasz & Dale 2002).
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4. EFFECTS OF ANTIPLATELET AGENTS ON PLATELET 
PROCOAGULANT ACTIVITY (PCA)
The dominant effect of antiplatelet agents is the inhibition of platelet activation at the site of 
vascular injury under higher shear rates, thus leading to reduced aggregation and thrombus 
formation. This inhibition of platelet accumulation naturally leads to a quantitative de-
crease in platelet-dependent coagulation activity by diminishing the access of procoagulant 
phospholipid membranes and platelet secretion products at the thrombus site. However, 
antiplatelet agents may also exert direct qualitative effects on the procoagulant capacity of 
platelets. Theoretically, this inhibition of platelet procoagulant capacity could be achieved
by reduced release of 1) negatively charged procoagulant phospholipids on the outer surface
of activated platelets, 2) procoagulant agents such as FVa from platelet secretory granules, 
3) microparticles, or 4) plasminogen activator inhibitor (PAI)-1 (which in turn could result 
in enhanced fi brinolysis). 
4.1. Aspirin, dipyridamole and clopidogrel
To date, relatively little is known about the direct effects of the most widely used antiplatelet 
drugs on platelet-dependent activation of coagulation. Szczeklik et al. (1986) fi rst showed 
that aspirin induced delayed generation of thrombin, whereas Reverter et al. (1996) re-
ported only a modest decrease in thrombin generation and peak thrombin level induced by 
aspirin, both in vitro and in vivo, at concentrations that completely inhibited arachidonic 
acid-triggered aggregation. Butenas et al. (2001) observed no signifi cant affect of ingested 
aspirin (325 mg × 2/d for 3 days) on TF-induced thrombin generation in whole blood,
assessed by thrombin-antithrombin III (TAT) complex formation or fi brinopeptide A release.
Also, addition of 5 μM dipyridamole to blood had no effect on platelet-dependent coagula-
tion activity in their study. Vanschoonbeek et al. (2004) obtained similar results using the 
calibrated thrombogram method. Blocking of the purinergic ADP receptor P2Y12 has been 
shown to reduce platelet PCA in an animal model (Herault et al. 1999) and in human plate-
lets (Storey et al. 2000, Vanschoonbeek et al. 2004).
4.2. Glycoprotein IIb/IIIa antagonists
Three parenteral GPIIb/IIIa antagonists – abciximab, tirofi ban, and eptifi batide – are cur-
rently available for clinical use. These agents have been used for the short-term treatment 
of patients undergoing percutaneous coronary intervention (PCI) or with acute coronary 
sydromes (ACS). The goal of treatment is to aggressively inhibit GPIIb/IIIa-mediated 
platelet aggregation for a short time (24–72 h) during the period of highly elevated risk 
of platelet thrombus formation. To achieve benefi cial effects, doses of GPIIb/IIIa antago-
nists target 80% receptor occupancy of unstimulated platelets, whereas more extensive 
occupancy causes marked prolongation of bleeding time (Coller et al. 1989 and 1991). In 
addition to blocking platelet aggregation, GPIIb/IIIa antagonists also inhibit the outside-in 
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signaling that follows the binding of adhesive ligands to the activated receptor (Shattil et 
al. 1998). This signaling results in further platelet spreading, granule secretion, clot re-
traction, GPIIb/IIIa receptor activation, and expression of procoagulant activity (Casserly 
& Topol 2002). 
Abciximab
Abciximab (c7E3 Fab, ReoProR, EliLilly/Centocor) is a parenteral chimeric antibody frag-
ment currently approved for use in patients undergoing PCI, although it has been studied 
in patients with ACS as well. It is a high-affi nity GPIIb/IIIa antagonist with a dissociation 
constant (Kd) of 5 nmol/L, resulting in a predominantly receptor-bound distribution fol-
lowing administration (Kleiman 1999). The binding site of abciximab on the GPIIb/IIIa 
receptor seems to be distinct from the ligand-binding site, since abciximab is able to bind 
to the receptor even if it is occupied by a RGD peptide. Abciximab also interacts with the 
vitronectin receptor αvβ3 on platelets, endothelial cells, and smooth muscle cells, as well 
as with the activated MAC-1 (αMβ2) receptor on leukocytes (Coller 1999). Abciximab has
a slow, up to 4 h, half-time rate of dissociation from the GPIIb/IIIa receptor and it re-
distributes to other platelets in vivo (Mascelli et al. 1998). While plasma levels of abciximab
fall quickly after infusion, platelet-bound abciximab can be detected for up to 15 days after 
treatment (Mascelli et al. 1998), and shear-induced platelet deposition remains abnormal 
for up to one week after treatment (Osende et al. 2001). 
Tirofi ban
Tirofi ban (AggrastatR, MSD) is a synthetic parenteral non-peptide tyrosine derivative that 
mimics the RGD integrin recognition sequence (Hartmanet et al. 1992, Egbertson et al. 
1994). It is highly selective for the GPIIb/IIIa receptor and competitively inhibits platelet 
aggregation by occupying the binding pocket of the receptor (Kleiman 1999). Tirofi ban 
is approved for use in patients with ACS, although it has been used in several studies in 
patients undergoing PCI. It is a lower affi nity antagonist with a Kd of 15 nmol/L, and the 
unbound fraction of the infused drug accounts for approximately 35% of the total circulating
pool. It has a rapid off-rate with a dissociation half-time of only about 10 s, and normal 
platelet function is restored within 3–4 h after discontinuation of infusion (Kereiakes et al. 
1999).
Eptifi batide
Eptifi batide (IntegrilinR, Schering-Plough/COR Therapeutics) is a synthetic parenteral
cyclic heptapeptide demonstrating a high specifi city for the GPIIb/IIIa receptor by its KGD
sequence and binding to the ligand-binding pocket of the receptor (Phillips & Scarborough 
1997). It is a low-affi nity antagonist with a Kd of 120 nmol/L and has a rapid onset of action. 
Due to the rapid dissociation of the drug, restoration of normal platelet function occurs within 
4 h of cessation of infusion. Eptifi batide is currently approved for use both in patients with 
ACS and in patients undergoing PCI.  Low levels of Ca2+ in ex vivo or in vitro studies con-
ducted in trisodium citrate-anticoagulated blood dimish the fi brinogen-binding affi nity of the 
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GPIIb/IIIa receptor and facilitate binding of eptifi batide, thus leading to an enhanced inhibi-
tory effect of eptifi batide compared to its clinical effi cacy in vivo (Phillips et al. 1997).
Clinical effi cacy
The greatest clinical impacts of parenteral GPIIb/IIIa antagonists have been demonstrated 
in patients undergoing PCI. In a pooled analysis of all placebo-controlled PCI trials (Fig. 
8), the absolute and relative risk reduction in the composite 30-day endpoint of death and 
myocardial infarction (MI) was 2.9 and 34%, respectively (Casserly & Topol 2002). Pla-
cebo-controlled trials have suggested a more pronounced reduction in MI and urgent re-
vascularization after PCI with abciximab (EPIC 1994, EPILOG 1997, EPISTENT 1998) when
compared with eptifi batide (IMPACT 1997, ESPRIT 2000) or tirofi ban (RESTORE 1997) 
in patients undergoing angioplasty or stenting. The 30-day outcome of the TARGET trial 
(Topol et al. 2001a) confi rmed the superiority of abciximab over tirofi ban in patients un-
dergoing PCI. Reduction of mortality has been reported only with abciximab, and becomes 
manifest only during long-term follow-up. 
Fig. 8. Death or non-fatal myocardial infarction (MI) outcomes at 30 days in randomized placebo-
controlled trials of parenteral GPIIb/IIIa antagonists. Risk ratio (RR) with 95% CI, size of RR box 
being proportional to total sample size. Frequency of death or non-fatal MI in columns 5 and 6. 
Reproduced with permission from Casserly & Topol 2002. ACS: acute coronary syndromes; PCI: 
percutaneous coronary intervention; PTCA: percutaneous transluminal coronary angioplasty. 
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In ACS (unstable angina and non-ST elevation MI), the small-molecule GPIIb/IIIa 
antagonists eptifi batide, tirofi ban, and another non-peptide antagonist lamifi ban, have
demonstrated effi cacy as a component of medical therapy alone or when combined with 
PCI or surgical revascularization (PRISM 1998, PRISM-PLUS 1998, PURSUIT 1998, 
PARAGON 1998), although the benefi t has been more modest than that observed in PCI 
trials (an overall absolute and relative risk reduction in incidence of death and MI at 30 
days of 1.4% and 11%, respectively) (Chew & Moliterno 2000). The role of abciximab in 
the treatment of patients with ACS is obscure. In one study, abciximab has shown a benefi t 
in patients with ACS who undergo PCI following a prolonged infusion both during the 
medical treatment phase and following PCI (CAPTURE 1999). In contrast, the more recent 
GUSTO IV study demonstrated no benefi t of abciximab when used as medical therapy 
alone for patients with ACS (Simoons 2001). 
In patients with acute ST-elevation MI, a combination of GPIIb/IIIa antagonists to 
full-dose thrombolytic therapy led to increased bleeding complications. In the GUSTO V 
study with abciximab plus half-dose reteplase versus full-dose reteplase alone, signifi cant 
reductions in reinfarction, recurrent ischemia and urgent revascularization were observed 
with combination therapy, but without any mortality benefi t (Topol 2001b). The ASSENT-3 
trial also demonstrated a marked reduction in reinfarction, no mortality benefi t, and excess 
of bleeding complications with the combination of abciximab and tenecteplase (ASSENT-3 
2001).
Oral GPIIb/IIIa antagonists
Several oral GPIIb/IIIa antagonists have been evaluated in phase III clinical studies: 
sibrafi ban (SYMPHONY 2000), lotrafi ban (Topol et al. 2000), orbofi ban (Cannon et al. 
2000), and xemilofi ban (O’Neill et al. 2000). These all are non-peptide prodrugs that have 
to undergo one or more entzymatic steps to become an active drug, and generally elicit low 
bioavailability. To date, all studies with oral GPIIb/IIIa have failed to demonstrate a benefi t 
in the settings of PCI and ACS. A meta-analysis reported a signifi cantly increased risk in 
mortality and major bleeding without any effect on MI, whereas the need for urgent revas-
cularization was reduced (Chew et al. 2001).
Parenteral GPIIb/IIIa antagonists and platelet procoagulant activity
The fi rst observation of the effect of platelet GPIIb/IIIa blockade on coagulation activity 
came from evaluation of the EPIC study. Moliterno et al. (1995) reported that activated 
clotting times (ACT), used to monitor heparin dosing in the interventional laboratory, were 
signifi cantly prolonged in patients receiving abciximab compared to placebo during PCI. 
This fi nding was confi rmed in vitro by Ammar et al. (1997), both in heparinized blood and 
in blood anticoagulated with the direct thrombin inhibitors hirudin and PPACK. Moreover, 
thrombin generation induced by platelets from patients with Glanzmann thrombastenia is 
also reduced when compared with normal platelets (Gemmel et al. 1993, Reverter et al. 
1996, Weiss & Lages 1997). Several in vitro and ex vivo studies have demonstrated that GP 
IIb/IIIa antagonists reduce platelet-dependent thrombin generation (Reverter et al. 1996, 
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Dangas et al. 1998, Keularts et al. 1998, Pedicord et al. 1998, Rao et al. 1999, Li et al. 
2000), expression of negatively charged phospholipids and binding of FV/Va on the plate-
let surface (Furman et al. 2000), and procoagulant microparticle formation (Gemmel et al. 
1993, Reverter et al. 1996). All in vitro studies have utilized isolated platelets in suspension, 
PRP, or whole blood and activated platelets with soluble agonists rather than with perma-
nent adhesion to a thrombogenic surface. While one study suggested that the anticoagulant 
effect of abciximab was due to blockade of both GPIIb/IIIa and the vitronectin receptor 
αvβ3 (Reverter et al. 1996), other investigators have reported that the effect is exclusively 
mediated by blockade of GPIIb/IIIa (Ammar et al. 1997, Furman et al. 2000, Lages & 
Weiss 2001). Byzova and Plow (1997) reported a novel link between platelets and blood 
coagulation by showing that prothrombin binds to platelet GPIIb/IIIa in a cation-dependent 
manner and this interaction accelerates prothrombin activation to thrombin. This binding 
was inhibited by different peptide ligands and monoclonal antibodies against GPIIb/IIIa, 
suggesting another possible mechanism underlying the anticoagulant effect of GPIIb/IIIa 
antagonists. 
The contents of platelet secretory granules mediate several important effects on plate-
let activation, coagulation, fi brinolysis, infl ammation, and atherogenesis. Given the central 
role of GPIIb/IIIa in platelet activation, the blockade of this receptor was initially assumed 
to elicit benefi cial effects on thrombus propagation in part through inhibition of platelet 
secretion. So far, studies have provided controversial results. Reverter et al. (1996) initially 
observed reduced release of platelet factor (PF) 4 and platelet-derived growth factor in 
response to c7E3. Several investigators have reported mild or no antisecretory effects of 
abciximab (Tsao et al. 1997, Furman et al. 2000, Klinkhardt et al. 2000), tirofi ban (Furman 
et al. 2000), or eptifi batide (Furman et al. 2000), whereas others have suggested paradoxi-
cally accelerated secretion induced by abciximab and eptifi batide (Schneider et al. 2000).
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AIMS OF THE STUDY
Despite the important functional role of platelets in directing thrombus formation at the 
site of arterial injury, relatively little is known about their procoagulant activity induced 
by adhesion to a thrombogenic surface. The aim of this thesis was to investigate the effect 
of fi rm adhesion on the procoagulant activity of platelets and the role of specifi c platelet 
glycoprotein receptors mediating this activation. We set out to develop a new adhesion-
dependent assay to assess platelet-mediated activation of coagulation upon two thrombo-
genic surfaces: 1) collagen, as an initial platelet-adhesive surface in arterial injury; and 2) a 
plasma clot, as a model of a preformed thrombus promoting sustained interaction between 
platelets and the coagulation system.
The study focused on the following specifi c issues:
1. Characteristics and interindividual variability of adhesion-induced platelet pro-
coagulant activity.
2. The roles of glycoprotein IIb/IIIa and Ib receptors in adhesion-induced platelet pro-
coagulant activity and release of PF 4.
3. Effects of the three clinically administered GP IIb/IIIa antagonists – abciximab, 
tirofi ban, and eptifi batide – on adhesion-dependent platelet PCA and aggregation
induced by various procoagulant platelet agonists.
39
Methods
METHODS
1. BLOOD COLLECTION AND ANTICOAGULANTS
Blood was obtained from healthy non-smoking volunteers who had not taken any medica-
tion during the preceeding 14 days. Free-fl owing blood was collected via venipuncture 
from a cubital vein with a 16- or 17-gauge polytetrafl uoroethylene cannula (BOC Ohmeda 
AB) in supine position after a 20-minute rest. The fi rst 3 ml were collected in ethylenedi-
aminetetraacetic acid (EDTA) for blood cell counts and hematocrit assessed with a Throm-
bocounter Coulter T-540 (Coulter Electronics Inc, USA). For plasma separation, nine
volumes of blood were collected into one volume of 0.109 or 0.129 M trisodium citrate. For 
platelet-rich plasma (PRP) blood was anticoagulated with 0.109 M trisodium citrate (II-IV) 
or with 40 μmol/L PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone, Cal-
biochem-Novabiochem Co) (III, IV). For gel-fi ltered platelets (GFP), blood was collected 
into polypropylene tubes containing 131 mmol/L acidic citrated dextrose (pH 4.5), at a ratio 
of one volume to six volumes of blood. For whole blood perfusions with subsequent pro-
coagulation studies (III) only minimal anticoagulation, 1 μmol/L D-phenylalanyl-L-prolyl-
L-arginine chloromethylketone (PPACK), was used to allow initial thrombin generation.
2. POOLED AND DEFIBRINATED PLASMA
Pooled citrated platelet-poor plasma (PPP) from 10 donors was prepared by repeated cen-
trifugation (1500 g, 10 min, 22°C). Plasma fi brinogen (assessed by the functional method 
of Clauss; normal range, 2.0 to 4.0 mg/mL), prothrombin fragments (F1+2) (Enzygnost 
F1+2 micro, Behring; normal, <1.1 nmol/L), thrombin-antithrombin complexes (TAT) 
(Enzygnost TAT micro; Behring; normal, ≤4.1 μg/L), and D-dimer (Asserachrom D-Di, 
Diagnostica Stago; normal, <400 ng/mL), as well as the global coagulation tests (aPTT, 
thrombin time, and PT) in the pooled plasma were all within normal ranges.
Pooled plasma was defi brinated essentially as described in Hemker et al. (1993), and 
used as the source of pro- and anticoagulant factors to avoid clot formation and uncontrolled 
loss of soluble thrombin during the procoagulation assay (Liu et al. 1979, Kumar et al. 1994). 
One volume of reptilase (STA-reptilase, Diagnostica Stago) was added to 49 volumes of 
citrated plasma, incubated for 5 min at 37°C and for 10 min on ice. Then the clot was cen-
trifuged (2100 g, +4°C) for 10 min to separate the plasma. In this reptilase-treated plasma F 
1+2, TAT, and D-dimer were all within normal ranges. Ristocetin (1mg/ml, Sigma)-induced 
aggregation of GFP in defi brinated plasma indicated normal function of VWF.
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3. PLATELET PREPARATION
PRP was separated from whole blood after centrifugation (180 g, 12 min, 22ºC), and plate-
let count was adjusted with PPP when needed. GFP were prepared from PRP as reported 
previously by Timmons and Hawiger (1989). To control platelet activation during the fi ltra-
tion, small doses of apyrase (1 U/mL, Sigma) and PGE1 (25 ng/mL, Sigma) were added to
PRP. Platelets suspended in HEPES buffer without cations were eluted through a Sepha-
rose CL-2B column (Pharmacia LKB Biotechnology Inc, Sweden). Isolated platelets were 
diluted in HEPES buffer to different densities (10–300 × 106/mL) and divalent cations 
were added just before experiments. For specifi c adhesion experiments (II) GFP were
supplemented with 1) pooled citrated plasma, 2) fi brinogen-depleted pooled plasma, 3) 
commercial FVIII- and VWF-defi cient plasma (Sigma), or 4) antithrombin III-immuno-
depleted plasma (American Diagnostica Inc) to a fi nal density of 100 × 106/mL.
4. ADHESIVE SURFACES (I–III)
4.1. Collagen
Collagen-coated coverslips for static experiments (I–III) were prepared by applying Horm 
collagen-reagent (Nycomed) at 25 μg/mL in the buffer provided (isotonic glucose solution, 
pH 2.7 to 2.9, 100 μL/coverslip) on round plastic Thermanox coverslips (area 1.77 cm2, 
Nunc), incubated for 1 h at 37°C in a humid chamber and washed three times in PBS. For 
perfusion studies (III) 9 μL of Horm collagen suspension was repeatedly smeared on plas-
tic Permanox coverslips (25×75 mm, Nunc), washed with a neutralizing buffer (Williams et 
al. 1978), and incubated for 30 min in a moist chamber at 37ºC. Bovine serum albumin (2% 
BSA, Sigma) in phosphate-buffered saline (PBS) was used as a control substrate as well as 
to block the collagen-coated coverslips.
4.2. Plasma clots
Plasma clots (I–III) were generated from pooled citrated plasma (diluted 1:2 in PBS, 100 
μL/coverslip) by recalcifi cation (5 mmol/L CaCl2) and addition of bovine α-thrombin (Dade, 
0.1 U per coverslip) on Thermanox coverslips. The fi nal concentration of ionized calcium 
in this 1:2 diluted citrated plasma was physiological, 1.1 mmol/L (Microlyte 6, Kone In-
struments, Finland, reference values, 1.1–1.3 mmol/L). The plasma clots were incubated 
for 30 min at 37°C in a humid chamber and for 30 min at room temperature. Thereafter, the 
clot-coated coverslips were washed six times in PBS. 
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4.3. Fibrin surfaces
Fibrin surfaces (II) were prepared from a 100 μL solution of plasminogen- and VWF-free 
human fi brinogen (Enzyme Research Laboratories) (2 mg/mL in PBS) by either 0.5 U of 
α-thrombin or 0.5 BU of reptilase (Diagnostica Stago) in the presence of 2 mmol/L CaCl2, 
incubated for 1 h at 37°C, and washed in PBS.
5. PLATELET DEPOSITION ON ADHESIVE SURFACES (I–III)
5.1. Labeling of platelets
For quantitating platelet deposition on a thrombogenic surface in the static adhesion
experiments (I-III), PRP or GFP were incubated with 10 nmol/L 3H-serotonin (5-hydroxy 
(G-3H)tryptamine creatinine sulphate, Amersham) at 37°C for 15 min (Mustonen & Lassila 
1996). At this serotonin concentration platelet membranes are labeled without contribution 
of the 5-HT2A-receptor, controlled by a 5-HT2A-receptor blocker ketanserin (unpublished 
data). In whole blood perfusion experiments (III), PRP was fi rst separated and platelets 
were labelled with 3H-serotonin before reconstituting with the remaining blood cells.
5.2. Adhesion assay
In an adhesion assay (I–III) 3H-serotonin-labeled GFP (supplemented with 2 mmol/L CaCl2 
and 1 mmol/L MgCl2) were allowed to adhere on a thrombogenic surface in the presence or 
absence of inhibitors at 37ºC for 30 min under slow rotation. In adhesion experiments with 
PRP or plasma-supplemented GFP (II), MnCl2 (2 mmol/L) was used instead of CaCl2 and 
MgCl2 to ensure functional GPIIb/IIIa receptors without inducing coagulation. 
The deposited 3H-activity was measured by liquid scintillation counting. All data on 
platelet deposition are expressed in numbers of 3H-positive platelets per cm2 of coverslip 
area. In the case of plasma clots the number of deposited 3H-positive platelets was corrected 
with the amount of 3H-serotonin released: 3H-scintillation activity in the platelet suspension 
and release of serotonin into plasma were measured in tubes with imipramine-formalde-
hyde on ice (centrifuged at 9 500 g for 2 min) (Holmsen & Dangelmaier 1989). 
In addition, adhesive surfaces were occasionally studied with scanning electron micro-
scopy (SEM) (JEOL-820 or Zeiss DSM 962) as previously reported (Siljander et al. 1996).
5.4. Effect of thrombin on platelet adhesion to plasma clots
To study the effect of thrombin on platelet (GFP 100 × 109/L) adhesion to plasma clots (II) 
we inhibited thrombin with its physiological antagonist antithrombin III (Atenativ, a kind 
gift from Octapharma, 0.05–10 U/mL). Alternatively, 1 U/mL unfractionated heparin (Leo 
Pharma), 1 U/mL enoxaparin (Klexane, Aventis Pharma), 25 U/mL recombinant hirudin 
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(Calbiochem) or 10 μmol/L PPACK (Calbiochem) were preincubated with GFP (100 × 
109/L) for 10 min before adhesion. The selected concentrations of these thrombin inhibitors 
prolonged thrombin time (with 1 U/mL thrombin) to over 300 s. Optionally, plasma clots 
were preincubated with the thrombin inhibitors before the adhesion experiment.
5.5. Effect of fi brin polymerization on platelet adhesion to plasma clots
The effect of fi brin polymerization during platelet adhesion to clots (II) was assessed with 
GPRP (0.5 or 1 mmol/L, Bachem) added to GFP (100 × 109/L) 10 min before adhesion. 
These concentrations of GPRP prolonged thrombin time without affecting thrombin-
induced aggregation of GFP (PACKS-4, Helena Laboratories) or the activity of thrombin 
on a chromogenic substrate (S-2238, Chromogenix).
6. PLATELET PROCOAGULANT ACTIVITY
6.1. Two-stage PCA assay: Generation of thrombin on adhesion-
activated platelets (I–III)
Adhesion-induced platelet procoagulant activity (Fig. 9) was studied upon two thrombo-
genic surfaces: 1) collagen, as an initial platelet-adhesive surface in arterial injury, and 
Procoagulant Activity Assay
defibrinated
plasma
immobilized collagen/fibrin on a coverslip
adhesion of GFP
addition of coagulation factors and Ca2+
soluble thrombin
chromogenic measurement
 (S-2238)
Fig. 9. Two-stage procoagulant activity assay. Gel-fi ltered platelets (GFP) were fi rst allowed to ad-
here to a thrombogenic surface in the presence of 2 mM CaCl2 and 1 mM MgCl2. Coagulation was 
initiated on the adhered platelets by incubating with 1:20 diluted defi brinated pooled plasma and 
traces of tissue factor, and thrombin generation was assessed chromogenically (S-2238).
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2) plasma clots, to model a preformed thrombus promoting sustained interaction between 
platelets and coagulation. 
In the fi rst phase, GFP (in 2 mM CaCl2- and 1 mM MgCl2-supplemented HEPES 
buffer) were allowed to adhere to a thrombogenic surface in the presence or absence of 
inhibitors for 30 min at 37°C under slow rotation, and the coverslips were washed in PBS 
to remove unattached platelets.
In the second phase, coagulation was initiated on the adhesion-activated platelets by 
incubating with defi brinated 1:20 diluted pooled plasma (500 μL) with or without tissue 
thromboplastin (1:5000 fi nal concentration of Thromborel S, Behringwerke AG). Defi bri-
nated plasma was used as a source of clotting factors and to prevent clot formation with 
unpredictable binding of thrombin during the assay. Thrombin generation was stopped with 
an equal volume of stopping buffer (125 mM NaCl, 50 mM Tris-HCl, 2 mM EDTA; pH 
7.9) (Heemskerk et al. 1999) and measured with a chromogenic substrate S-2238 (For de-
tails, see I). Time-dependence of the thrombin generation induced by the adhered platelets 
was assessed at various time-points ranging between 2 and 30 min. The amount (U/mL) of 
soluble thrombin formed was assessed with a standard curve of α-thrombin. This thrombin 
generation was then adjusted with the number of deposited platelets, as assessed simul-
taneuosly with radiolabeled platelets.
6.2. PCA of adhered platelets in comparison with PCA of activated 
platelets in suspension (I)
The procoagulant activity of collagen-adherent platelets was compared with that of an 
equal number of GFP in suspension after their activation with 10 μg/mL thrombin receptor
activating peptide (TRAP, SFLLRN, Bachem) and 10 μg/mL collagen, or 10 μmol/L
calcium ionophore A23187 (Sigma). Platelets were fi rst activated either by adhesion to a 
collagen surface or by the soluble agonists. Coagulation was initiated with defi brinated 
plasma and tissue thromboplastin, and thrombin generation was measured with S-2238 at 
the time when maximal thrombin generation was reached.
6.3. One-stage PCA assay: Generation of thrombin on PRP clots (I, II)
The procoagulant effect of platelets (I) and contribution of GPIIb/IIIa or GPIb on this ac-
tivity (II) was also studied in a one-stage procoagulation assay with PRP clots (Fig. 10). 
PRP was adjusted to 100–300 × 109 platelets/L with PPP and diluted 1:2 in PBS. PRP clots 
(100μL, corresponding fi nally to 5–15 × 106 platelets in the clot) were prepared on a Ther-
manox coverslip by recalcifi cation (15 mmol/l CaCl2) and treatment with 0.1 U of bovine 
α-thrombin. The platelet-containing clots were incubated at 37°C for 15 min and washed 
three times in PBS. Plasma clots without platelets were prepared identically from PPP. To 
assess the procoagulant activity of the clots, the PRP clots and their PPP controls were 
incubated with 1:20 diluted defi brinated pooled plasma and traces of tissue thromboplastin 
(1:5000 fi nal concentration of Thromborel S) at 37°C for 10 min under slow rotation. Clots 
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PRP clot assay
PRP (5-15 x 106 plt) + Ca++ + thrombin
defibrinated plasma
Addition of coagulation factors and Ca++
soluble thrombin
Chromogenic measurement  (S-2238)
were also incubated with PBS buffer only to estimate the amount of soluble thrombin origi-
nating from the clot. These absorbance values were subtracted from the results obtained 
with plasma. Thrombin generation was stopped and determined as described above.
6.4. Prothrombin fragments (F1+2) (I–III)
The capacity of surface-adherent platelets to promote thrombin generation was also
estimated with F1+2 after adhesion of GFP to a thrombogenic surface. Subsequently, GFP 
suspensions (9 vol) were collected in a platelet-inhibitory anticoagulant (Teitel et al. 1982) 
(one vol), centrifuged immediately (11 000 g, 5 min, 4°C), and the supernatant subjected 
to ELISA.
6.5. Platelet-derived microparticles (MP) in PCA of adhered platelets (I)
MP generation during adhesion-induced platelet activation was studied in GFP supernatant 
after the adhesion assay. After removal of non-adhered platelets by centrifugation in the 
presence of apyrase (1 U/mL) and PGE1 (25 ng/mL) to avoid platelet activation, the TF-
triggered procoagulant activity of the supernatant was studied after addition of defi brinated 
Fig. 10. Platelet-rich plasma (PRP) clot assay. PRP clots were prepared on a coverslip by recalci-
fi cation and treatment with thrombin. Coagulation was initiated by incubating PRP clots and their 
platelet-poor plasma (PPP) controls with 1:20 diluted defi brinated pooled plasma and traces of tissue 
thromboplastin, and thrombin generation was assessed chromogenically at 10 min. For details, see 
text. 
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pooled plasma and tissue thromboplastin. To confi rm the role of soluble platelet-derived 
microparticles in supporting coagulation activation after the adhesion-induced platelet ac-
tivation, the PCA of the supernatant was measured both in the presence of MP and after 
their fi ltration (0.1 μm Millipore, Ireland). Furthermore, the procoagulant activity of the 
MP-supernatant was adjusted with the number of adhered platelets on collagen or clots 
(studied with radiolabel).
6.6. Whole blood perfusions (III)
The effects of different GP IIb/IIIa antagonists on adhesion-induced platelet PCA was fur-
ther assessed by whole blood perfusions using the Turitto perfusion chamber with defi ned 
rheological characteristics (Hall et al. 1998). The concentrations of the GPIIb/IIIa antago-
nists were selected to inhibit 80% of ADP-induced aggregation response in PPACK-PRP. 
PPACK (1 μM)-anticoagulated blood was divided into 7.5 mL aliquots and incubated with 
10 μg/mL abciximab (ReoproR, EliLilly/Centocor), 100 ng/mL tirofi ban (AggrastatR, MSD), 
1 μg/mL eptifi batide (IntegrilinR, Schering-Plough), or a buffer control at 37°C for 5 min 
before single passage for 1 min over a collagen-coated coverslip at a shear rate of 1600 s-1. 
Afterwards, the coverslip was briefl y perfused with PBS, then rinsed once with buffer to 
fl ush the unattached cells. Platelet deposition was assessed with 3H-serotonin labeled plate-
lets as described above and occasionally with SEM. Surfaces obtained during simultaneous 
perfusions without platelet labeling were subjected to coagulation assay as in the two-stage 
assay described above. 
7. PLATELET FACTOR 4 (II,III)
To further assess adhesion-induced platelet activation, we measured α-granule release of 
platelet factor (PF) 4 (ELISA, Asserachrom PF 4, Diagnostica Stago) after adhesion of 
GFP to collagen or clots. After the adhesion assay samples were collected into a platelet-
inhibitory anticoagulant (Teitel et al. 1982), centrifuged (11 000 g, 5 min, 4°C), and the 
supernatant assayed.
8. AGGREGATION (III–IV)
Platelet aggregation was assessed with a PACKS-4 turbidometric aggregometer (Helena 
Laboratories) to defi ne equivalent concentrations of different GPIIb/IIIa antagonists (III) 
or to study the effects of these antagonists on platelet activation induced by various pro-
coagulant agonists (IV). Citrated or PPACK-anticoagulated PRP, or GFP (in HEPES with
2 mmol/L CaCl2 and 1 mmol/L MgCl2) were stirred with various concentrations of GPIIb/IIIa
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antagonists or buffer control at 37°C for 1 min before adding the agonist. The effect of 
fi brin polymerization during platelet aggregation was controled with GPRP (1 mmol/L) 
added 10 min before the aggregation. The rate of primary aggregation (min-1) and extent 
of maximal aggregation (%) at 5 min were assessed. The inhibition of aggregation brought 
about by the GPIIb/IIIa antagonists was calculated from these data. 
9. STATISTICAL ANALYSIS
N refers to the number of blood donors. The experiments were performed in duplicates or 
triplicates. Data are expressed as mean ± standard deviation (SD), unless indicated other-
wise. Differences amongst independent groups were tested using unpaired student’s t-test, 
whereas differences between paired data were evaluated by paired student’s t-test. The 
threshold for statistical signifi cance was set at a p-value <0.05. 
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RESULTS
1. PROCOAGULANT ACTIVITY (PCA) OF ADHERENT PLATELETS
1.1. Effect of adhesion on platelet PCA
To assess the effect of permanent adhesion to a thrombogenic surface on PCA we compared 
the procoagulant capacity of collagen-adherent platelets to that of activated platelets in 
suspension (I). Thrombin generation was initiated on collagen-adherent platelets or equal 
number of maximally activated platelets in suspension by incubation with 1:20 diluted 
pooled defi brinated plasma and a trace amount of tissue thromboplastin, and fi nally de-
termined chromogenically after 10 min. To avoid uncontrolled binding of thrombin to the 
newly forming fi brin we used defi brinated plasma as the source of coagulation factors and 
natural anticoagulants. When  adjusted for platelet number, collagen-adhered GFP sup-
ported 30% more thrombin generation than maximally, with TRAP and collagen or with 
calcium ionophore, activated GFP in suspension under equal conditions (p<0.01 for TRAP 
plus collagen, p<0.05 for calcium ionophore) (I, Fig.6). Thus, fi rmly adhered platelets on 
a thrombogenic surface showed markedly enhanced PCA when compared with platelets in 
suspension, even after their strong activation.
1.2. Platelet adhesion to a thrombogenic surface
To dissociate platelet adhesion to a thrombogenic surface and the subsequent platelet ag-
gregation upon the initial adherent layer, GFP were labeled with 3H-serotonin and there-
after diluted in HEPES buffer at different platelet counts (10–300 × 109/L) (I). At platelet 
densities of up to 100 × 109/L, mainly single platelets were attached on collagen surfaces or 
plasma clots, whereas higher platelet densities supported further aggregation on the initially 
adhered platelets. Thus, at the lower density scanning electron micrographs depict GFP 
(100 × 109/L) as a single adhesive layer on collagen or plasma clots and show fully spread 
“fried egg” forms with pseudopod extensions, whereas at the higher density (300 × 109/L) 
extensive platelet aggregation was triggered under equal conditions (I, Fig. 4).
1.3. Individual variation in platelet adhesion and subsequent PCA
Individual differences in platelet deposition to collagen or a plasma clot were studied with 
platelets from 6 healthy donors (I, Figs. 3A and 3B). At platelet densities of up to 100 × 
109/L only minor interindividual differences in deposition occurred on both substrates, but 
higher densities showed over 3-fold variability. This individual variability in platelet depo-
sition was triggered mainly by varying aggregation, especially on plasma clots. Equally, 
the platelet counts of the supernatants after deposition on collagen or plasma clots were 
diminished owing to platelet aggregation (I, Figs. 3C and 3D, respectively). 
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Individual variation in adhesion-induced platelet PCA was studied with unlabeled 
platelets obtained from the same donors. Again, thrombin generation was initiated on the 
collagen- or clot-adherent platelets by 1:20 diluted pooled defi brinated plasma with tissue 
thromboplastin and determined chromogenically after 10 min. Although platelet deposition 
on collagen or plasma clots did not markedly vary at platelet densities up to 100 × 109/L, 
thrombin generation induced by these adhered platelets varied almost 4-fold (I, Figs. 5A 
and 5B). 
1.4. PCA of platelets deposited on collagen versus on plasma clot
At all densities, platelet deposition to plasma clots was 2–3 times higher than on collagen 
surfaces (I, Figs. 3A and 3B). Data from the adhesion and subsequent procoagulation ex-
periments were used to adjust platelet-induced thrombin generation to the number of
adhered platelets on the thrombogenic surface (I, Fig. 5C). This platelet adhesion-
quantitated generation of soluble thrombin was up to 5-fold greater on collagen than on 
plasma clots (p<0.05), although it attenuated with increasing platelet densities, suggesting 
the importance of the initial adherent layer for adhesion-induced platelet PCA.
The rate of thrombin generation after adhesion-triggered platelet activation and the 
effect of tissue thromboplastin were studied in a two-stage procoagulation assay at several 
time-points ranging between 2 and 30 min (I, Fig. 2). Thrombin was formed signifi cantly 
faster upon clot-adherent platelets than upon platelets bound to collagen. After initial ac-
tivation over the plasma clots, tissue thromboplastin did not improve the maximal rate or 
extent of platelet-dependent thrombin generation. In contrast, thrombin generation upon 
collagen-bound platelets progressed slowly, but tissue thromboplastin accelerated it almost 
4-fold.
1.5. PCA of soluble platelet-derived microparticles
MP formation during platelet adhesion and subsequent MP-induced procoagulant activity 
were studied in GFP supernatants after adhesion to collagen or a plasma clot, with BSA as 
a control surface (I, Fig.7). After a 30 min adhesion of GFP (100 × 109/L), the non-adherent 
platelets were removed from the supernatant by centrifugation, and the tissue thromboplas-
tin-triggered thrombin generation in 1:20 diluted pooled defi brinated plasma was measured 
in the presence of soluble MP and after their removal by fi ltration. On collagen, the throm-
boplastin-induced thrombin generation after MP fi ltration decreased by 32±6% (p<0.05). 
After clot-induced platelet activation, MP fi ltration reduced the PCA of the supernatant by 
43±14% (p<0.05). When the PCA of the soluble MP was adjusted by the number of initially 
adhered platelets on collagen or a clot, MP-induced thrombin generation per 106 adhered 
platelets on collagen was over 3-fold more than on clots (p=0.01).
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2. GPIIb/IIIa ANTAGONISTS AND ADHESION-DEPENDENT 
PLATELET PCA
2.1. Effect of abciximab on platelet deposition on adhesive substrates
Platelet deposition on collagen or a plasma clot was studied with 3H-serotonin labeled GFP 
(100 or 300 × 109/L, supplemented with 2 mmol/L CaCl2 and 1 mmol/L MgCl2) in the presence
and absence of abciximab (c7E3) (II). Abciximab decreased platelet deposition on
collagen, especially at higher concentrations allowing aggregation (II, Fig. 1A). However, 
deposition of isolated platelets on plasma clots remained unaltered (GFP 100 × 109/L) or 
even increased (GFP 300 × 109/L) in the presence of abciximab (II, Fig.1B). In the scan-
ning electron micrographs the typical platelet aggregation upon clots was diminished by 
abciximab and instead the clot surface appeared completely covered with single platelets 
(II, Fig.2). 
To disclose this accelerating effect of abxicimab on the deposition of GFP on plasma 
clots, we assessed the roles of 1) soluble or clot-bound thrombin, and 2) platelet-derived 
fi brin(ogen) during the adhesion assay (II). In the presence of the physiological plasma 
anticoagulant antithrombin (AT), or either indirect (unfractionated heparin or low-molecu-
lar-weight heparin) or direct (hirudin or PPACK) thrombin inhibitors, platelet adhesion 
to plasma clots declined equally in the presence and absence of abciximab (II, Fig. 5B). 
The impact of the newly forming soluble thrombin on deposition of GFP on clots was 
evidenced in the presence of increasing concentrations of AT (II, Fig. 5A). In the absence 
of AT abciximab failed to inhibit platelet deposition, but even at low concentrations (0.1 
U/mL) AT markedly improved the inhibitory effect of abciximab (p<0.001).  While inhibi-
tion of fi brin polymerization with GPRP did not reduce adhesion of GFP (100 × 106/mL), 
the accelerating effect of abciximab was completely abolished (p<0.001) (II, Fig. 5C). In 
contrast, inhibitors of thrombin or fi brin polymerization did not affect platelet adhesion to 
collagen in the presence of abciximab (data not shown). The concentrations of GPRP used 
in these experiments prologed thrombin time without affecting thrombin-induced platelet 
aggregation in GFP or chromogenic (S-2238) thrombin activity. 
The role of clot-bound thrombin on platelet deposition and the abciximab-induced 
acceleration of platelet deposition on plasma clots was confi rmed upon thrombin- or rep-
tilase-induced fi brin surfaces (prepared from isolated fi brinogen in the absence of other 
plasma proteins) (II). In parallel with the plasma clots, abciximab increased deposition of 
GFP (300 × 106/mL) on thrombin-induced fi brin surfaces (12.2 ± 1.1 vs 18.9 ± 6.9 × 106 
platelets/cm2, p<0.01, n=3), and again GPRP abolished this abciximab-triggered accelera-
tion (9.3 ± 1.1 vs 8.1 ± 1.3 × 106 platelets/cm2, n=3). In the presence of a thrombin inhibitor 
(10 μmol/L PPACK) or with reptilase-induced fi brin surfaces platelet deposition attenuated 
5-fold, fully neutralizing the infl uence of abciximab (2.6 ± 0.2 vs 2.8 ± 0.4 × 106 platelets/
cm2 in the presence of PPACK, and 2.3 ± 0.3 vs 2.4 ± 0.5 × 106 platelets/cm2 on reptilase-
treated fi brin surfaces). 
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Next, deposition of GFP to clots was assessed in the presence or absence of plasma in 
the platelet suspension (II). To allow functional GPIIb/IIIa without activation of coagula-
tion and subsequent clot formation platelets were supplemented with 2 mM MnCl2 (instead 
of calcium and magnesium). GFP (100 × 106/mL) deposited on plasma clots to the same 
extent in the presence of different cations (data not shown). Upon addition of normal or 
defi brinated plasma to the platelet suspension, abciximab clearly decreased deposition of
GFP to clots, as it did in PRP (100 × 106/mL), suggesting an inhibitory aid by some plasma
proteins (other than fi brinogen). In the presence of VWF- and FVIII-defi cient plasma 
abciximab also decreased platelet deposition. In AT-depleted plasma deposition of GFP 
increased and the inhibitory effect of abciximab was reduced (II, Fig. 6).
2.2. Effect of abciximab on adhesion-induced platelet PCA
Thrombin generation was initiated on collagen- or plasma clot-adherent platelets by incu-
bation with 1:20 diluted pooled defi brinated plasma and traces of thromboplastin. When ad-
justed by the number of adhered platelets on collagen or a clot, abciximab reduced platelet-
associated thrombin generation by 35% on average (range 10–75%, p<0.03), irrespective 
of the thrombogenic surface (II, Figs. 3A and 3B). Thrombin generation was also measured 
by soluble F1+2 during platelet (GFP 100 × 106/mL) adhesion to plasma clots. Compatible 
with the chromogenic thrombin activity, the levels of F1+2 were 38% lower (51.3 ± 5.1 vs. 
32.1 ± 2.8 nmol/L, p<0.005) in the presence of abciximab.
2.3. Procoagulant activity of PPP and PRP clots
The roles of platelet GPIIb/IIIa and GPIb receptors on platelet-derived PCA were studied 
in a one-stage assay of PPP and PRP clots (II). Abciximab or SZ2, a monoclonal antibody 
against GPIb, did not affect the procoagulant activity of PPP clots, but the 5-fold higher 
thrombin generation upon PRP clots (with 15 × 106 platelets) was reduced by 38% or 44% 
when abciximab or SZ2, respectively, was present in the clot (p<0.03). This inhibitory
effect of abciximab on platelet-dependent thrombin generation was equal to that observed 
in the two-stage assay and with F1+2 after platelet adhesion to plasma clots. In the presence 
of both abciximab and SZ2 platelet-dependent generation of soluble thrombin on PRP clots 
was reduced by 65%. 
2.4. Effects of different GPIIb/IIIa antagonists on adhesion-dependent 
platelet PCA
Next, we compared the effects of the three clinically available GPIIb/IIIa receptor antago-
nists – abciximab, tirofi ban and eptifi batide – on the procoagulant activity of platelets ad-
hered to a collagen surface or plasma clot (III). To determine the equipotent concentrations 
of the different GPIIb/IIIa antagonists for further PCA experiments, we fi rst studied the 
dose-responses of the antagonists upon maximal aggregation to 5 μM ADP in PPACK-PRP 
(III, Fig. 1A-C) or to 0.05 U/mL thrombin in GFP (III, Fig. 1D-F). 
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For static PCA experiments with isolated platelets the concentrations of the GPIIb/IIIa 
antagonists were selected to maximally inhibit 1) thrombin-induced aggregation of GFP (III, 
Fig. 1 D-F), and 2) the procoagulant activity of collagen-adherent platelets in the two-stage 
PCA assay (III, Fig. 2). In the static assay GFP (100 × 109/L) were fi rst allowed to adhere to 
collagen for 30 min under slow rotation, and thrombin generation was triggered on the adhe-
sion-activated platelets as described above. Deposition of 3H-serotonin-labeled GFP (100 × 
109/L) to collagen (0.57 ± 0.2 × 106 plt/cm2 in control) was equally inhibited (p<0.001 for 
all antagonists) in the presence of 10 μg/mL abciximab (40% reduction), 50 ng/mL tirofi ban 
(51% reduction), or 1 μg/mL eptifi batide (46% reduction) (III, Fig. 3 A). Despite this rela-
tively equal inhibition of platelet deposition to collagen, the adhesion-dependent procoagu-
lant capacity of these same platelets (without radiolabel) (0.74 ± 0.18 U/mL, mean ± SD) was 
differentially inhibited by the antagonists. In the two-stage PCA assay, platelet-dependent 
thrombin generation was attenuated most with abciximab, by 49%, in comparison to 31% 
with tirofi ban (p<0.05), or 27% with eptifi batide (p<0.005) (III, Fig. 3 B). 
Thrombin generation was also measured by soluble F1+2 during deposition of GFP 
(100 × 109/L) to a plasma clot in the presence of 10 μg/mL abciximab, 100 ng/mL tirofi ban, 
1 μg/mL eptifi batide or buffer control (III, Fig. 4). Again, the levels of F1+2 after platelet 
deposition to clots were 21% lower in the presence of abciximab than with tirofi ban or ep-
tifi batide, compatible with the thrombin generation upon collagen-adherent platelets. 
2.5. Platelet PCA after whole blood perfusion over collagen
For whole blood perfusion experiments the concentrations of GPIIb/IIIa antagonists were 
selected to inhibit ADP-induced aggregation in PPACK-PRP by 80% (III, Fig 1 A-C). 
Platelet deposition to collagen was determined after 1 min blood perfusions at a shear rate 
of 1600 s-1 with 3H-serotonin-labeled platelets in the presence of 10 μg/mL abciximab, 
100 ng/mL tirofi ban, 1 μg/mL eptifi batide, or a buffer control. At these concentrations all 
GPIIb/IIIa antagonists effi ciently and equally reduced platelet deposition on collagen by 
approximately 90% (III, Figs. 5 and 6). The procoagulant capacity of these perfusion-
adhered platelets (unlabeled) on the collagen coverslip was assessed as described under static
conditions by incubating with diluted defi brinated plasma and tissue thromboplastin (III). 
Again, compatible with the static assay utilizing isolated platelets and either collagen or 
clot surfaces, abciximab reduced the generation of soluble thrombin on collagen-adherent 
platelets 35% more than tirofi ban (p<0.001) or eptifi batide (p<0.01) (III, Fig. 5).
2.6. Effects of GPIIb/IIIa antagonists on PF 4 release
Release of PF 4 from platelet α-granules during adhesion of GFP (100 × 109/L) to colla-
gen or clots was studied in the presence of GPIIb/IIIa antagonists at 10 μg/mL abciximab, 
100 ng/mL tirofi ban, or 1 μg/mL eptifi batide (III). In general, platelets depositing on clots 
released more PF 4 than those depositing on collagen (98±7 vs 68±15 U/mL, p=0.02). 
Irrespective of the thrombogenic surface, all three of the GPIIb/IIIa antagonists failed to 
modulate PF 4 release during platelet deposition (III, Table 1). 
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3. GPIIb/IIIa ANTAGONISTS AND GPVI-MEDIATED PLATELET 
AGGREGATION
Turbidometric aggregation with ADP as a standard agonist has been the method most used 
to assess the pharmacodynamics of GPIIb/IIIa antagonists. Appreciating the central role 
of GPVI in mediating collagen-induced platelet activation, we assessed the inhibitory ef-
fects of three currently available GPIIb/IIIa receptor antagonists – abciximab, tirofi ban, 
and eptifi batide – on platelet aggregation induced by ADP or by various GPVI-mediated 
agonists (IV). Under conditions that equally inhibited over 80% of ADP-triggered platelet
aggregation in PPACK-anticoagulated PRP, abciximab inhibited convulxin- and CRP-
induced platelet aggregation signifi cantly more effectively than the low-molecular weight 
antagonists (p<0.005) (Fig. 11). All agents inhibited convulxin-induced aggregation more 
effectively (abciximab 90±6%, tirofi ban 64±20%, and eptifi batide 61±14%) than compatible
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Fig. 11. Inhibition of platelet aggregation by glycoprotein (GP) IIb/IIIa antagonists. PPACK-an-
ticoagulated platelet-rich plasma (300 × 109/L) was preincubated with buffer control, 10 μg/mL 
abciximab, 100 ng/mL tirofi ban, or 1 μg/mL eptifi batide before triggering platelet aggregation with 
5 μM ADP, 1 μg/mL Horm collagen, 10 ng/mL convulxin, or 0.5 μg/mL CRP. Maximal aggregation 
data of 10 donors are expressed as mean ± SD. *p<0.005. ADP: adenosine diphosphate; CRP: colla-
gen-related peptide; PPACK: D-phenylalanyl-L-prolyl-L-arginine chloromethylketone; SD: standard 
deviation.
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CRP-induced aggregation (abciximab 75±18%, tirofi ban 41±7%, and eptifi batide 41±6%) 
(p<0.01 for all). In contrast, Horm collagen-induced aggregation was completely inhibited 
with all antagonists under equal conditions. In addition, TRAP-induced platelet aggrega-
tion in PPACK-PRP was effectively and equally inhibited by all GPIIb/IIIa antagonists at 
the same concentrations (data not shown). 
The superior inhibitory effect of abciximab on GPVI-mediated platelet aggregation 
was observed at the agonist concentrations that induced maximal aggregation. Howev-
er, when the concentrations of these triggering agonists were increased 5- to 10-fold, all
antagonists reached a similar level of inhibition, that is only 35±5% in the case of convulxin 
and 31±3% in the case of CRP (IV, Fig. 2). In the dose-response studies of the GPIIb/
IIIa antagonists (IV, Fig. 3) the inhibition of convulxin- or CRP-triggered aggregation in 
PPACK-PRP seemed to reach a plateau at the same concentration of abciximab (10 μg/mL) 
as in ADP-induced aggregation, but 3-fold higher concentrations of tirofi ban (300 ng/mL) 
or eptifi batide (3 μg/mL) were needed for the same effect.
3.1. Effect of divalent cations on inhibition of platelet aggregation
The role of divalent cations in the inhibitory effects of the antagonists was studied in citrate-
anticoagulated PRP (IV). After chelation of divalent cations all GPIIb/IIIa antagonists
equally inhibited convulxin- and CRP-triggered aggregation up to 70% (abciximab 60–
69%, tirofi ban 65–69%, and eptifi batide 71–74%, at the concentrations described above). 
Higher concentrations of GPIIb/IIIa antagonists (abciximab 30 μg/mL, tirofi ban 500 ng/
mL, or eptifi batide 5 μg/mL) failed to potentiate this inhibitory effect. 
3.2. Inhibition of fi brin polymerization during platelet aggregation
Next, we assessed the effect of an inhibitor of fi brin polymerization, i.e. GPRP (1.0 mmol/L),
on the inhibitory capacity of the GP IIb/IIIa antagonists (IV, Fig. 4). GPRP had no effect
on convulxin- or CRP-triggered aggregation in PPACK-PRP in the absence of GPIIb/IIIa 
antagonists. However, it signifi cantly potentiated the inhibitory effect of tirofi ban and
eptifi batide, whereas the effect of abciximab remained unaltered. After preincubation with 
GPRP the maximal aggregation in the presence of tirofi ban or eptifi batide was on average 
65% (tirofi ban 59%, p=0.03, eptifi batide 72%, p=0.01) or 44% (tirofi ban 43%, p=0.005, 
eptifi batide 45%, p=0.001) less after activation of platelets with convulxin or CRP, respec-
tively. 
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DISCUSSION
It is now well established that the interaction between blood platelets and coagulation fac-
tors is essential for hemostasis and thrombosis, especially at the higher shear rates found 
in arteries. But despite the important role of activated platelets in directing the coagulation 
system at the site of vascular injury, relatively little is known about platelet PCA triggered 
by their permanent adhesion to a thrombogenic surface. Most studies have monitored the 
procoagulant effects of platelets following activation in suspension. However, platelets are 
by nature adhesive elements which perform their hemostatic function under fl ow condi-
tions. It is therefore likely that studies on platelets in suspension do not necessarily refl ect 
the wide range of platelet functional responses to vascular injury. 
Our study design provided activation of platelets by their fi rm adhesion, with subse-
quent procoagulant alteration of the phospholipid membrane. The importance of permanent 
adhesion for platelet PCA became evident when compared with that of platelets in suspen-
sion. Platelets activated by adhesion to a collagen surface supported 30% more thrombin 
generation than an equal number of platelets in suspension, even after maximal activation. 
Previously, Haimovich et al. (1993) have reported enhanced α2β1 integrin-mediated plate-
let activation upon immobilized ligand compared with soluble ligand applied to platelets 
in suspension, and studies with immobilized monomeric collagen under fl ow conditions 
supported the same conclusion (Polanowska-Grabowska et al. 1993, Gear et al. 1997). 
Recently, adhesion of platelets to a monolayer of a α2β1-specifi c peptide GFOGER induced 
spreading and shape change in the presence of inhibitors of secondary mediators, even 
though the peptide had no effect on platelet activation in suspension (Inoue et al. 2003). 
In concordance with our fi ndings, Heemskerk et al. (1997) observed that interaction of 
platelets with immobilized collagen could lead to exposure of procoagulant phopholipids, 
whereas in previous studies collagen was unable to induce procoagulant activation when 
applied to platelets in suspension in the absence of thrombin (Bevers et al. 1982). Equally, 
the GPVI-specifi c ligand CRP was ineffective in inducing platelet PCA when added to
isolated platelets resuspended in buffer, whereas adhesion of platelets to a CRP-coated cover-
slip caused strong procoagulant activation (Heemskerk et al. 1999). Further, platelets ad-
hered to fi brinogen also showed potentiated activation by convulxin or CRP compared with 
platelets in suspension (Siljander et al. 2001). This enhanced adhesion-triggered activation 
could well be due to the capacity of the adhesive substrate to support platelet spreading and 
cytoskeletal extension, thus promoting effective signaling crucial to platelet procoagulant 
activation as well as providing more membrane accessibility for coagulation factors. In 
addition, augmented accessibility of glycoprotein receptors from the SCCS during shape 
change and spreading of adhering platelets (Escolar et al. 1989) could be related to the en-
hanced procoagulant capacity of platelets. 
Several studies have demonstrated a signifi cant increase in the presence of GPIb on the 
luminal side of spread platelets after activation under static (Escolar et al. 1994, White et 
al. 1995) or fl ow (White et al. 1994) conditions. Studies on GPIIb/IIIa receptor expression 
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after surface activation of platelets have provided contradictory results presumably due to 
varying experimental conditions (reviewed in Escolar & White 2000). Revealed by fl ow 
cytometric analysis, only a minor fraction (10–15%) of platelets were directly activated 
upon incubation with even extremely high (50 μg/mL) concentrations of fi brillar collagen 
in suspension, and further platelet activation was reliant on the release of secondary media-
tors, i.e. ADP and TXA2 (Nieswandt et al. 2001b). These data and the fact that in vivo colla-
gen is present as a monolayer further underlines the importance of adhesion for subsequent 
platelet activation.  However, at the site of vascular injury, only the initial layer of adherent 
platelets are in contact with collagen, whereas further platelet activation is mediated by ad-
hesion to the newly-forming fi brin clot with active clot-bound thrombin (Kumar et al. 1994 
and 1995). Thus, procoagulant transformation occurs precisely at the sites where coagula-
tion is desired (exposed subendothelial collagen) or already present (fi brin clot). 
The contribution of fl ow conditions and other blood cells was assessed in the whole 
blood perfusion experiments, although the limitations of our study include the use of de-
fi brinated and diluted plasma and the absence of vascular endothelium. Instead of purifi ed 
coagulation factors, we used defi brinated pooled plasma as a source of procoagulants to 
eliminate uncontrolled binding of the newly-forming thrombin to the fi brin clot, and to 
overcome the effects of natural anticoagulants. In the presence of plasma fi brinogen under 
similar conditions, measurable soluble thrombin was on average 28% lower owing to clot 
formation and thrombin binding to the newly-forming fi brin. The report by Kumat et al. 
(1994) also indicated that ≈30% of all thrombin formed during coagulation activation is 
adsorbed onto fi brin. Inhibitors of activated coagulation factors in plasma, such as TFPI, 
APC, and AT, also play a major role in regulating and localizing the coagulation activa-
tion. Only a portion of the total amount of activated factors will be bound to cell surfaces. 
The factors that are surface-bound are relatively protected from plasma protease inhibitors, 
while soluble factors are more rapidly inactivated. Thus, those activated factors that do not 
remain localized on a cell surface (or bound to the forming fi brin clot) are inhibited and pre-
vented from catalyzing coagulation reactions in the systemic circulation. When this control 
mechanism is overwhelmed, disseminated intravascular coagulation ensues.   
At lower platelet densities, allowing mainly adhesion, the individual variation in platelet 
deposition on collagen and plasma clots was relatively modest. However, at higher platelet
densities deposition markedly (2- to 4-fold) varied between donors, owing to increased
aggregation. This varying aggregation during the fi rst step of the assay refl ected individual
differences in platelet activation, since in the absence of plasma it was mediated by plate-
let-derived ligands: fi brinogen, VWF, or thrombospondin. Although platelet deposition on 
collagen or plasma clots showed only modest variation with platelet densities up to 100 × 
109/L, thrombin generation induced by these adhered platelets varied over 3-fold independ-
ent of the thrombogenic surface, refl ecting donor-dependent differences in the procoagulant 
capacity of platelets. Similar evidence of interindividual variation in platelet procoagulant 
activity has previously been reported (Monroe et al. 1994, Kumar et al. 1995, Sumner
et al. 1996), although the precise pathophysiological mechanisms are still unknown. Furihata
et al. (2001) observed a 5-fold range in platelet GPVI content in healthy subjects and
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demonstrated that GPVI-mediated prothrombinase activity was directly proportional to 
the GPVI content of platelets. There is good evidence that platelet GP polymorphisms are 
linked to receptor expression and/or functional heterogeneity of platelets (reviewed in Yee 
& Bray 2004), but their association with platelet procoagulant capacity remains unclear.
Recently, a low-frequency allele of GPVI was reported to be associated with reduced
surface expression and functional responses, including signifi cantly lower thrombin-
generating potential (Joutsi-Korhonen et al. 2003). However, results of studies on the
association of platelet GP receptor polymorphisms with the risk of arterial thrombosis have 
so far been contradictory (Kunicki 2002, Yee & Bray 2004). 
We observed several differences in platelet deposition and subsequent PCA depending 
on the adhesive surface. Platelet deposition on plasma clots was signifi cantly greater than 
on collagen surfaces, especially at higher platelet densities allowing aggregation. The rate 
of thrombin generation induced by clot-adherent platelets was markedly faster than that of 
collagen-adherent platelets during the initial phase of coagulation activation. As previously
reported (Heemskerk et al. 1999), thrombin generation proceeded slowly on collagen-
adherent platelets in the absence of tissue thromboplastin, while no coagulation activity 
was observed in the absence of both platelets and exogenous tissue thromboplastin under 
these experimental conditions. The presence of thromboplastin clearly enhanced platelet-
dependent coagulation activity more effi ciently than thrombin generation in plasma without 
platelets. These fi ndings are compatible with the idea that although TF is not absolutely 
necessary, the interaction between TF and activated platelets induces a local rapid thrombin 
burst at the site of vessel injury. In vivo, endothelial damage causes simultaneous exposure 
of collagen and TF, an integral membrane protein of subendothelial cells, allowing optimal 
response to vascular injury. On the contrary, when the clot has already formed, it contains 
thrombin and additional clotting factors, so that the role of TF is less crucial. 
When platelet-dependent thrombin generation in the two-stage assay was adjusted by 
the number of adhered platelets, the collagen-adherent platelets in the presence of throm-
boplastin generated up to 5 times more soluble thrombin than the clot-adherent platelets. 
However, the interindividual variation in platelet procoagulant capacity was surface-inde-
pendent. Platelet-adjusted thrombin generation decreased at increased platelet densities, 
underlining the importance of the initial adhesive layer on coagulation activity, with restric-
tion on excessive platelet plug formation (Coller et al. 1993, Heynen et al. 1994, Kirch-
hofer et al. 1995, Wencel-Drake et al. 1996). Moreover, in larger platelet aggregates, only 
the superfi cial layer of activated platelets may come into contact with plasma coagulation 
factors and thus effectively contribute to thrombin generation. 
Activation of platelets by their fi rm adhesion to collagen or a plasma clot was
accompanied by formation of platelet-derived procoagulant MP. Again, when MP-dependent
thrombin generation was adjusted by the number of adherent platelets from which the MP 
originated, soluble thrombin generated by MP from collagen-adherent platelets exceeded 
that of the clot. This fi nding may be explained by the quantity and/or quality of the MP 
produced by collagen-adherent platelets. In addition, these surface-associated differences 
may be related to the retention of the newly-forming thrombin (Kumar et al. 1994) as well 
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as MP (Siljander et al. 1996) on the fi brin clot. Retained thrombin and MP then contribute 
to the rapid coagulation activity on the clots while lower amounts of soluble thrombin and 
numbers of MP are detected in the supernatant.
In conclusion, our fi ndings demonstrate the major differences between collagen and 
plasma fi brin clots as adhesive and thrombogenic surfaces. First, the initial activation of 
platelets by adhesion to subendothelial collagen leads – in the presence of traces of TF 
– to a marked burst of thrombin and platelet-derived MP into the circulation. Second, the
subsequently forming clot, through contributing to explosive platelet adhesion and
coagulation activation, retains signifi cant amounts of active thrombin and numbers of
procoagulant MP, thus localizing the process at the site of vascular injury. 
The contribution of specifi c adhesive platelet receptors and their ligands responsible
for enhanced PCA has only recently gained interest. GPVI is considered the principal
receptor mediating the procoagulant activation induced by platelet adhesion to collagen 
(Heemskerk et al. 1999, Goto et al. 2002, Siljander et al. 2004), and platelet adhesion per 
se potentiates the procoagulant activation mediated by GPVI (Siljander et al. 2001), pos-
sibly by triggering additional activation steps or by ensuring optimal GPVI-ligand contact. 
In this study, we set out to assess the roles of GPIIb/IIIa and GPIb receptors on adhesion-
induced platelet PCA. As expected, blockade of GPIIb/IIIa with abciximab lowered platelet 
deposition to collagen by inhibiting aggregation upon the initial layer of adherent platelets.
In addition, abciximab reduced the procoagulant capacity of these remaining collagen-
adherent platelets by 30%. Surprisingly, platelet deposition to plasma clots was not reduced in
the presence of abciximab, although the formation of typical aggregates seemed inhibited. 
However, platelet-dependent thrombin generation was reduced by almost 40% despite the 
full surface coverage of single platelets. A similar inhibitory effect of abciximab on platelet-
dependent coagulation activity was confi rmed by reduced generation of soluble F1+2 dur-
ing platelet adhesion to plasma clots and also in the one-stage procoagulation assay, where 
the procoagulant capacity of PRP clots – but not of PPP clots – was attenuated. This sup-
ports a true effect on platelet-mediated thrombin generation, not a direct infl uence on the 
coagulation system. These fi ndings are in accordance with previous studies with platelets in 
suspension or whole blood. It has been reported that GPIIb/IIIa antagonists reduce platelet-
dependent thrombin generation (Reverter et al. 1996, Byzova & Plow 1997, Keularts et al. 
1998, Furman et al. 2000, Li et al. 2000, Dicker et al. 2001), expression of procoagulant 
phopholipids and binding of FXI and FV/Va on the platelet surface (Furman et al. 2000), 
and formation of procoagulant microparticles (Gemmel et al. 1993, Reverter et al. 1996). In 
these studies the inhibitory effect of abciximab on platelet-dependent thrombin generation 
ranged between 25 and 60%. In our hands, abciximab reduced adhesion-triggered platelet-
dependent thrombin generation by 30–40%, although we have previously observed that the 
procoagulant capacity of fi rmly adhered platelets on a thrombogenic surface exceeds that 
of even maximally activated platelets in suspension. 
The monoclonal antibody against GPIb, SZ2, clearly inhibited adhesion-induced 
platelet PCA, without affecting platelet deposition to collagen or plasma clots. Similar
results have been obtained in previous studies with platelets in suspension. Beguin et al. 
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(1999) showed that GPIb and VWF are required in fi brin-associated platelet PCA during 
TF-induced coagulation. In a report by Dörmann et al. (2000) the thrombin-binding site of 
GPIb was essential for thrombin-induced platelet procoagulant activity, which also required 
PAR-1, GPIIb/IIIa, and platelet-to-platelet contact. In addition, Bernard-Soulier platelets 
lacking GPIb have reduced procoagulant capacity (Dicker et al. 2001, Beguin et al. 2004). 
When combining SZ2 and abciximab the procoagulant capacity of PRP clots in the one-
stage assay was further inhibited, supporting the involvement of both GPIb and GPIIb/IIIa 
in platelet procoagulant activation. However, this combined inhibition was not complete, 
since 35% of the maximal platelet procoagulant capacity remained, suggesting alternative 
mechanisms for platelet PCA. Beguin et al. (2004) have recently reported similar results,
whereas in the study of Dicker et al. (2001) co-inhibition of GPIb and GPIIb/IIIa
completely blocked procoagulant activity of normal platelets. This discrepancy is likely 
due to different experimental conditions, since Dicker et al. assessed thrombin-induced 
PCA of isolated platelets with purifi ed coagulation factors in the absence of fi brin(ogen), 
whereas we, as well as Beguin et al., used PRP. Indeed, Beguin et al. (2004) suggest that, in 
addition to thrombin, polymerizing fi brin is crucial for GPIb-mediated platelet procoagulant 
activity in a VWF-dependent manner. In addition, binding of FXI to GPIb (Keularts et al. 
2001, Baglia et al. 2002) may also affect GPIb-mediated platelet PCA. 
Accelerated deposition of GFP to plasma clots in the presence of abciximab was related
to clot-bound thrombin and polymerization of platelet-derived fi brin(ogen). In the presence 
of AT or thrombin inhibitors, deposition of GFP to clots decreased both in the presence 
and absence of abciximab. Accordingly, abciximab inhibited platelet deposition on fi brin 
surfaces prepared with reptilase but increased deposition on thrombin-induced fi brin clots. 
Inhibition of fi brin polymerization in GFP suspension abolished the accelerating effect of 
abciximab. Legrand et al. (1989) found that thrombin concentrations allowing fi brin po-
lymerization induces accelerated binding of secreted fi brinogen to the platelet surface, and 
this is markedly decreased when fi brin formation is inhibited with GPRP. Furthermore, 
upon platelet activation with thrombin, a ligand-occupied internal pool of α-granule GPIIb/
IIIa receptors is expressed on the platelet surface in a secretion-dependent manner (Nurden 
et al. 1996, Gawaz et al. 2000). Compatible with our results, abciximab fails to inhibit 
this expression of fi brinogen-bound GPIIb/IIIa receptors from the internal pool (Kleiman 
et al. 1995, Bihour et al. 1999). Thus, during platelet adhesion to plasma clots containing 
remarkable amounts of fi brin-bound thrombin, the internal GP IIb/IIIa -bound fi brin(ogen) 
may directly polymerize with the fi brin surface. Indeed, platelet adhesion to collagen and 
subsequent fi brin thickness were enhanced during an ex vivo perfusion with non-anticoagu-
lated blood from patients with Glanzmann thrombasthenia (Hainaud et al. 2002), as previ-
ously reported with a GPIIb/IIIa  antagonist lamifi ban (Kirchhofer et al. 1995). 
The roles of adhesive platelet receptors and their ligands in platelet procoagulant
activation are summarized in Fig. 12. Initially, platelet adhesion to subendothelial collagen
triggers the procoagulant alteration of this initial layer of adherent platelets at the site of 
vascular injury. According to current data, GPVI is the principal receptor mediating colla-
gen-induced procoagulant activation. Arterial thrombus progresses as a result of coagulation 
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activation leading to formation of thrombin and fi brin, and further platelet activation occurs 
on the surface of the fi brin clot through GPIIb/IIIa and GPIb receptors. In addition to the 
fi brin-VWF-GPIb pathway (Loscalzo et al. 1986, Beguin et al. 1999, Beguin et al. 2004), 
there is evidence that fi brin interacts with platelets with a greater affi nity than fi brinogen 
(Tuszynski et al. 1984, Legrand et al. 1989, Harfenist et al. 1985), and that this interaction 
occurs via GPIIb/IIIa receptors (Hantgan 1988). Recently, Phillips et al. (2004) observed 
that polymerized fi brin can function as a platelet co-stimulus by up-regulating expression of 
binding sites for FVIIIa in a GPIIb/IIIa-dependent manner. The resulting thrombin further 
accelerates procoagulant activation of platelets through binding to GPIb, PAR-1 and PAR-
4. Thus, the procoagulant activation of adherent platelets requires the concerted action of 
several platelet receptors at the site of arterial injury. It it likely that in vivo the pathways of 
platelet activation are dependent on the actual conditions, such as shear rate, level of tissue 
factor, and presence of thrombin or fi brin. Equally, the dominant mechanisms observed in 
vitro may be strongly related to the experimental conditions used.
Next, we compared the effects of the three currently available GPIIb/IIIa receptor an-
tagonists on the release reaction and PCA subsequent to deposition-induced activation of 
platelets both under static and blood fl ow conditions. To achieve benefi cial clinical effects, 
doses of GPIIb/IIIa antagonists target 80% receptor occupancy of unstimulated platelets, 
whereas excessive occupancy causes marked prolongation of bleeding time (Coller 1995). 
Turbidometric aggregometry is the most widely used method to assess the pharmacological 
effects of GPIIb/IIIa antagonists, and to select dosing for clinical trials. In fact, receptor 
occupancy studies with synthetic antagonists have been considered unreliable due to their 
lower affi nity and rapid off-rate (Casserly & Topol 2002). At concentrations that equally 
GP IIb/IIIa
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Fig. 12. From platelet adhesion to procoagulant activation. GP: glycoprotein; PAR; protease-activat-
ed receptor; PE: phosphatidylethanolamine; PS; phosphatidylserine, VWF; von Willebrand factor.
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inhibited platelet aggregation, all GPIIb/IIIa antagonists decreased the generation of new 
thrombin on the surface-deposited platelets. However, under all experimental set-ups
adherent platelets generated the least amount of thrombin in the presence of abciximab 
when compared with tirofi ban or eptifi batide. 
The existing data on the relative effects of different GPIIb/IIIa antagonists on platelet 
PCA are inconsistent. Pedicord et al. (1998) found equal inhibition of platelet PCA with 
abciximab and low-molecular-weight antagonists, whereas Furman et al. (2000) reported
abciximab to be a stronger inhibitor of platelet surface factor V/Va and annexin V binding than
tirofi ban and eptifi batide. Lages and Weiss (2001) showed that abciximab consistent-
ly inhibited (40–60%) collagen-activated or thrombin- and collagen-coactivated GFP,
whereas the non-antibody antagonists were weaker inhibitors of thrombin and collagen-
induced PCA and unable to inhibit collagen-induced platelet PCA. In the few clinical trials 
comparing different GPIIb/IIIa antagonists during PCI, abciximab was superior to tirofi ban 
(Topol et al. 2001a) and to eptifi batide (Lincoff et al. 2003). Different kinetics or binding 
sites of the antagonists on the GPIIb/IIIa receptor (Cierniewski et al. 1999, Kereiakes et al. 
2000, Jennings et al. 2000) may be associated with differences in platelet PCA or genera-
tion of platelet-derived MP. In later studies (Furman et al. 2000, Lages & Weiss 2001) the 
enhanced effect of abciximab was not mediated via the αvβ3 receptor, in contrast to a previ-
ous report by Reverter et al. (1996). Lages and Weiss (2001) postulate that the inhibitory 
effect of different GPIIb/IIIa antagonists relates to the agonist studied, a fi nding supported 
by GPIIb/IIIa-defi cient platelets (Weiss & Lages 1997). Also in our hands, the relative in-
hibitory effect of abciximab was stronger on collagen-adherent platelets than on platelets 
adhering to thrombin-induced plasma clots.
Independent of the thrombogenic surface, all GPIIb/IIIa antagonists failed to affect PF 
4 release from the adhering GFP, suggesting distinct mechanisms for procoagulant activa-
tion and the release reaction. Thus, the activated platelets at the site of thrombus formation 
preserve the ability to neutralize heparin therapy and also likely provide local stimulation 
of smooth muscle cell growth via platelet-derived growth factor. Previous reports on the 
effects of GPIIb/IIIa antagonists on α-granule release have provided contradictory results. 
Initially, Reverter et al. (1996) observed reduced PF 4 secretion in response to abciximab. 
In agreement with our results, Dickfeld et al. (2001) reported that abciximab, tirofi ban, 
and eptifi batide failed to inhibit P-selectin expression during platelet activation with ADP
or TRAP. Bihour et al. (1999) showed that during strong activation of isolated platelets
with TRAP abciximab had little effect on the secretion of P-selectin. Accordingly, secreted 
P-selectin was not signifi cantly reduced during abciximab infusion in patients undergoing 
PCI, when compared with samples taken before the medication. Equally, Neumann et al. 
(2001) found no signifi cant differences in the percentage of P-selectin positive platelets 
in patients undergoing PCI with abciximab, tirofi ban, or eptifi batide. In addition, several 
other studies have demonstrated mild or no antisecretary effects of abciximab (Klinkhard 
et al. 2000, Furman et al. 2000), tirofi ban (Furman et al. 2000, Schneider et al. 2000), and 
eptifi batide (Furman et al. 2000), whereas Schneider et al. (2000) reported paradoxical 
potentiation of  platelet secretion with abciximab and eptifi batide.
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Recent studies have placed the immunoglobulin superfamily member GPVI in a central
position in the complex processes of collagen-induced platelet activation, aggrega-
tion, degranulation and procoagulant activation (Nieswandt & Watson 2003, Farndale et al.
2004, Siljander et al. 2004, Moroi & Jung 2004). High-affi nity conformation of GPIIb/IIIa
in response to collagen-induced inside-out signalling seems to be mediated by GPIa/IIa 
and GPVI(-FcRγ), and further reinforced by the release of soluble mediators (Nakamu-
ra et al. 1999). We observed that inhibition of maximal platelet aggregation induced by 
various GPVI-related agonists depends on the agonist used, and that abciximab more
effectively than tirofi ban or eptifi batide reduced GPVI-mediated aggregation. Since GPVI 
is now considered as the key receptor in collagen-induced platelet procoagulant activa-
tion, these results give one explanation to previous observations of ours and others of the 
distinct inhibitory effects on platelet-dependent coagulation activity by various GPIIb/IIIa 
antagonists. This difference in the inhibitory capacity of these antagonists was dependent
on fi brin polymerization and divalent cations. Legrand et al. (1989) have shown that
intracellular fi brinogen from α-granules is expressed on activated platelets under conditions 
where binding of plasma fi brinogen is prevented by GPIIb/IIIa receptor antagonists. It has 
been suggested that the internal pool of GPIIb/IIIa on membranes of α-granules and the 
open surface canalicular system plays a role in this early and irreversible binding of platelet 
fi brinogen to its receptor, and that upon strong platelet activation this ligand-occupied pool 
of internal GPIIb/IIIa receptors is expressed on the platelet surface in a secretion-dependent
manner (Legrand et al. 1989, Nurden et al. 1996). Furthermore, Legrand et al. (1989)
demonstrated with thrombin-activated isolated platelets that rebinding of secreted fi brinogen
to GPIIb/IIIa on the platelet surface occurred only in the presence of thrombin concentrations
allowing fi brin polymerization, and was abolished in the presence of GPRP. These data are 
in accordance with our new fi ndings on the effect of GPRP on platelet aggregation in the 
presence of GP IIb/IIIa antagonists. Upon platelet activation with strong procoagulant ago-
nists in the presence of plasma, fi brinogen is exposed on the platelet surface and may po-
lymerize in response to thrombin generation upon the activated platelets. Abciximab seems 
to inhibit the procoagulant response to GPVI-mediated stimuli more effectively than the 
synthetic GPIIb/IIIa antagonists, leading to reduced fi brin polymerization and better inhibi-
tion of platelet aggregation. With weak procoagulant agonists, soluble collagen, TRAP and 
ADP, platelet aggregation was equally inhibited by all GPIIb/IIIa antagonists. In addition, 
they all reduced aggregation of GFP in suspension (devoid of coagulation activity) to the 
same level. To maintain normal levels of divalent cations during these experiments we used 
PPACK-anticoagulated PRP. In citrated PRP the inhibitory effects of various GPIIb/IIIa
antagonists did not differ from each other, refl ecting the importance of physiological
concentrations of divalent cations for normal binding of the antagonists to the receptor 
(Hourdille et al. 1985, Legrand et al. 1989, Phillips et al. 1997). Furthermore, although 
calcium does not accelerate thrombin-catalyzed fi brinopeptide release, it has a major role 
in the further polymerization of fi brin (Boyer et al. 1972).
Our fi ndings are relevant to several clinical issues. The data on the procoagulant acti-
vation of adherent platelets add to the awareness that platelets are not equal to phospholipid 
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vesicles in coagulation. In addition to procoagulant phospholipids, non-lipid receptors for 
coagulation factors (Bouchard et al. 1997, Byzova & Plow 1997, Baglia & Walsh 1998, 
Baglia  et al. 2002, Keularts et al. 2001, Ahmad et al. 2000) and platelet-derived FVa have 
been shown to infl uence platelet-dependent thrombin generation (Alberio et al. 2000). Due 
to the individual variation in platelet PCA, the role of platelet activation through adhe-
sive ligands should be considered in monitoring overall coagulation activity. The succesful
clinical use of GPIIb/IIIa antagonists may in part rely on their anticoagulant effects, which in
turn could affect the safety profi le of these drugs, especially in combination with anticoagu-
lants and fi brinolytics. Because of this dual role of platelets in hemostasis and thrombosis, it 
is evident that dosage of these drugs should not be based on platelet aggregation measure-
ments alone. We demonstrated that abciximab particularly well controls the thrombogenic-
ity of  collagen surfaces. This is compatible with the excellent effi cacy of abciximab  during 
percutaneous interventions upon exposure of fresh collagen and other subendothelial matrix 
during angioplasty and stenting, and its somewhat limited effi cacy with preformed throm-
botic surfaces as in the conservative treatment of unstable angina and myocardial infarction 
(Casserly & Topol 2002). The ability of a strong agonist to expose GPIIb/IIIa on the platelet 
surface in a preactivated, ligand-bound state is of considerable importance when evaluating 
the effects of antithrombotic drugs that inhibit fi brinogen binding to GPIIb/IIIa. Finally, 
we observed that GPIIb/IIIa antagonists exhibit distinct characteristic inhibition profi les. 
Careful evaluation of the specifi c effects of GPIIb/IIIa antagonists on platelet activation and 
procoagulant action in comparative clinical settings will undoubtedly identify the optimal 
applications and combinations with anticoagulants for these agents in the future. 
63
Conclusions
CONCLUSIONS
Permanently adhered and activated platelets on a thrombogenic surface display markedly 
enhanced procoagulant activity in comparison with maximally activated platelets in sus-
pension. Thus, adherent platelets strongly promote thrombus formation but, on the other 
hand, regulate the hemostatic integrity by localizing coagulation activity at the site of vas-
cular injury. Marked interindividual but surface-independent variation in adhesion-induced 
platelet PCA suggests a uniform platelet procoagulant mechanism. 
Additive reduction of platelet-dependent coagulation activity by blockade of GPIIb/
IIIa and GPIb receptors supports the involvement of both GPIIb/IIIa- and GPIb-mediated 
mechanisms of platelet procoagulant activity. However, that 35% of the maximal platelet 
procoagulant capacity remains suggests additional mechanisms for platelet procoagulant 
activity, likely GPVI and involvement of fi brin polymerization.
At similar anti-aggregatory effi cacy abciximab decreased thrombin generation on
adherent platelets more than tirofi ban or eptifi batide both under static and blood fl ow condi-
tions, dissociating aggregation and procoagulant activity. Independent of the thrombogenic 
surface, all GPIIb/IIIa antagonists failed to affect PF 4 release from the adhering platelets, 
suggesting distinct mechanisms for procoagulant activation and secretion.
GPIIb/IIIa antagonists exhibit distinct inhibition profi les in platelet aggregation trig-
gered by procoagulant GPVI-related platelet agonists. This difference was dependent on 
fi brin polymerization and divalent cations. During CRP- or convulxin-induced platelet ac-
tivation, inhibition of fi brin polymerization by GPRP potentiated the effects of tirofi ban and 
eptifi batide to reach that of abciximab, although GPRP did not affect platelet aggregation 
in the absence of GPIIb/IIIa antagonists. Thus, the ability of strong procoagulant platelet 
agonists to expose pre-activated and ligand-bound GPIIb/IIIa from the internal pool seems 
important.
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